<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001084" GROUP_ID="MUSKEL" ID="563499082413082743" MERGED_FROM="" MODIFIED="2008-11-09 00:29:49 +0100" MODIFIED_BY="Elizabeth Tanjong Ghogomu" REVIEW_NO="C065-R" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-11-08 18:25:03 -0500" MODIFIED_BY="[Empty name]">
<TITLE>Pharmacotherapy for Behcet's syndrome</TITLE>
<CONTACT>
<PERSON ID="5440" MODIFIED="2008-11-08 18:25:03 -0500" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Beverley</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Shea</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>bevshea@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart St.</ADDRESS_1>
<ADDRESS_2>Room 312</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 562 5800 ext: 8571</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-11-08 18:19:12 -0500" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<PERSON ID="19651" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Antonio</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Saenz</LAST_NAME>
<SUFFIX/>
<POSITION>Internist, Family Physician</POSITION>
<EMAIL_1>antoniosaenz@ya.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centro de Salud Pozuelo 1</DEPARTMENT>
<ORGANISATION>INSALUD - Madrid</ORGANISATION>
<ADDRESS_1>Emisora s/n</ADDRESS_1>
<ADDRESS_2/>
<CITY>Pozuelo de Alarcón</CITY>
<ZIP>28224</ZIP>
<REGION>Madrid</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 913 524 030</PHONE_1>
<PHONE_2>+34 913 516 404</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="F888F6EE82E26AA20093068AB994C60F" ROLE="AUTHOR">
<PREFIX>Dr.</PREFIX>
<FIRST_NAME>Monica</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ausejo</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>mausejo@h120.es</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Servicio de Farmacia Atencion Prinaria Area</DEPARTMENT>
<ORGANISATION/>
<ADDRESS_1>11 INSALUD, Benimamet 24-a</ADDRESS_1>
<ADDRESS_2/>
<CITY>Madrid</CITY>
<ZIP>28021</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>34 1 795 1297</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5440" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Beverley</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Shea</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>bevshea@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart St.</ADDRESS_1>
<ADDRESS_2>Room 312</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 562 5800 ext: 8571</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12662" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>George</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Wells</LAST_NAME>
<SUFFIX>PhD, MSc</SUFFIX>
<POSITION>Director</POSITION>
<EMAIL_1>gawells@ottawaheart.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cardiovascular Research Reference Centre</DEPARTMENT>
<ORGANISATION>University of Ottawa Heart Institute</ORGANISATION>
<ADDRESS_1>Room H1-1</ADDRESS_1>
<ADDRESS_2>40 Ruskin Street</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4W7</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 798 5555 x18640</PHONE_1>
<PHONE_2>+1 613 798 5555 x18642</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13312" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Vivian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Welch</LAST_NAME>
<SUFFIX/>
<POSITION>Research Associate</POSITION>
<EMAIL_1>vivian.welch@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Global Health, Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>One Stewart Street, Room 206</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 562-5800 ext: 2921</PHONE_1>
<PHONE_2/>
<FAX_1>+1 613 562-5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5474" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Tugwell</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>elacasse@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Global Health, Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613-562-5800 ext: 1945</PHONE_1>
<PHONE_2/>
<FAX_1>613-562-5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-11-08 17:52:54 -0500" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="24" MONTH="2" YEAR="1998"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="2" YEAR="1998"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="8" MONTH="11" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="1998"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-08 17:53:26 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-08 17:53:26 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
<P>CMSG ID: C065-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-08 17:54:07 -0500" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>CCOHTA. Canadian Coordinating Office for Health Technology Assessment .Ottawa</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Fondo de Investigaciones Sanitarias. Instituto de Salud Carlos III. Madrid</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>INSALUD. Madrid</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Clinical Epidemiology Unit, University of Ottawa. Ottawa</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-08 18:01:07 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-08 17:55:58 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-11-08 17:54:47 -0500" MODIFIED_BY="[Empty name]">Pharmacotherapy for Behcet's syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-08 17:55:58 -0500" MODIFIED_BY="[Empty name]">
<P>Behcet's syndrome is a multisystemic disorder presenting with recurrent oral and genital ulcerations as well as ocular involvement. Treatment of Behcet's syndrome is symptomatic and empirical.</P>
<P>Ten trials and 679 patients were included. There is insufficient evidence either to support or to refute some of the classic treatments for Behcet's syndrome, including colchicine, cyclophosphamide and steroids for eye involvement, azapropazone and colchicine for arthritis and acyclovir, colchicine and topical interpheron for aphthas. The results confirm the protective effects of cyclosporine and azathioprine for eye involvement and benzathine-penicillin for arthritis.</P>
<P>We conclude that further randomized, placebo-controlled, double-blind trials should be carried out to compare cyclosporine, azathioprine and benzathine-penicillin versus placebo in order to make the results generalizable and comparable.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Behcet's syndrome is a multisystemic disorder presenting with recurrent oral and genital ulcerations as well as ocular involvement. Treatment of Behcet's syndrome is symptomatic and empirical.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effects of available pharmacological interventions in treating the different clinical features of Behcet's syndrome.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Musculoskeletal Group's trials register, the Cochrane Controlled Trials Register, and Medline up to January 1998. The computer search was complemented by a hand search of all bibliographic references from the reference lists of included trials. Principal investigators were contacted to seek unpublished literature. All languages were included.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Studies were eligible if they fulfilled all of the four following criteria:<BR/>1. Randomized controlled trials, single or double-blind;<BR/>2. Participants were patients with Behcet's Syndrome as defined by the International Study Group, 1990 (Int Study Group 1990);<BR/>3. Interventions included any pharmacological therapy compared to placebo or some other pharmacological intervention for the treatment of Behcet's syndrome. <BR/>4. Outcome measures included active ocular inflammatory processes, arthritis, mucocutaneous manifestations (oral ulcer, genital ulcer, erythema nodosum), laboratory changes and major events such as adverse effects and death.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>The 32 potentially relevant references were assessed by two independent reviewers (MA, AS) according to the inclusion criteria. Ten trials fit the inclusion criteria and were included in this review. From the 10 included trials, data were independently extracted by the same two observers and cross checked. The quality of the included trials was assessed independently by two observers (MA, AS) using a validated scale (Jadad 1996).<BR/> <BR/>For dichotomous measures, the treatment effect for each trial was calculated using a fixed effect model [Peto model (Petitti 1994)]. The weighted mean differences were based, if available, on end-of-trial results. The analysis was conducted separately for each different intervention. Since the trials could not be pooled it was not possible to carry out a sensitivity analysis by quality scores or a subgroup analysis by drug dosages. Because of this lack of comparability across trials and the small number of trials, we could not conduct a heterogeneity test or a funnel plot.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Ten trials and 679 patients were included. There is insufficient evidence either to support or to refute some of the classic treatments for Behcet's syndrome, including colchicine, cyclophosphamide and steroids for eye involvement, azapropazone and colchicine for arthritis and acyclovir, colchicine and topical interpheron for aphthas. The results confirm the protective effects of cyclosporine and azathioprine for eye involvement and benzathine-penicillin for arthritis.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>We conclude that further randomized, placebo-controlled, double-blind trials should be carried out to compare cyclosporine, azathioprine and benzathine-penicillin versus placebo in order to make the results generalizable and comparable.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-08 18:01:07 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Behcet's syndrome is a multisystemic disorder presenting with recurrent oral and genital ulcerations as well as ocular involvement. In 1990, an international study group proposed standardized diagnostic criteria for Behcet's syndrome as follows: recurrent oral ulceration plus two of recurrent genital ulceration, eye lesions, skin lesions or pathergy test. The disease has a worldwide distribution with a prevalence ranging from 1:10,000 in Japan to 1:500,000 in Western countries. It affects mainly young adults (<LINK REF="REF-Int-Study-Group-1990" TYPE="REFERENCE">Int Study Group 1990</LINK>).</P>
<P>It is considered an autoimmune disease since vasculitis is the main pathologic lesion and circulating autoantibodies to human oral mucous membrane are found in approximately 50 percent of cases. Familial occurrence has been reported, and in patients from Eastern Mediterranean countries and Japan, the disease appears to be linked to HLA-B5 and HLA-DR5 alloantigens.</P>
<P>The oral recurrent aphthous ulcerations are usually painful, persist for one to two weeks and subside without leaving scars. Gastrointestinal involvement includes mucosal ulcerations of the gut. The genital ulcers resemble the oral ones. Skin involvement includes folliculitis, erythema nodosum or an acne-like exanthem. However, vasculitis is uncommon. Nonspecific skin inflammatory reactivity to scratches or intradermal saline injection (pathergy test) is a common and specific manifestation in Japanese and Eastern Mediterranean patients.</P>
<P>Eye involvement is the most dreaded complication, since it occasionally progresses rapidly to blindness. Eye involvement in Behcet's syndrome includes iritis, posterior uveitis, hypopyon uveitis, retinal vessel occlusions and optic neuritis.</P>
<P>The arthritis of Behcet's syndrome is not deforming. It can sometimes affect the knees and ankles. Superficial or deep peripheral vein thrombosis is seen in one fourth of the patients. Although pulmonary emboli is a rare complication, the superior vena cava is sometimes obstructed. Pulmonary artery vasculitis has been reported in 5 percent of patients (<LINK REF="REF-Moutsopoulos-1994" TYPE="REFERENCE">Moutsopoulos 1994</LINK>).</P>
<P>Central nervous system involvement includes benign intracranial hypertension, a multiple sclerosis-like picture, pyramidal involvement and psychiatric disturbances. Laboratory findings are mainly nonspecific indices of inflammation, although antibodies to human oral mucosae are also found. The severity of Behcet's syndrome abates with time. Apart from the cases with neurologic complications, life expectancy is usually unaffected, and the only serious complication is blindness.</P>
<P>Treatment of Behcet's syndrome is symptomatic and empirical. Topical corticoids have been used for mucous membrane involvement, rest and analgesics for arthritis, aspirin and dypiridamol for thrombophlebitis, and colchicine for mild forms of the syndrome. Systemic corticosteroid therapy and azathioprine or cyclosporine have been used for uveitis and central nervous system involvement.</P>
<P>With the emergence of new evidence in the last few years, there is a need for a systematic review to help guide clinicians in their treatment of these patients.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the efficacy of available pharmacological interventions in treating the different clinical features of Behcet's syndrome. These clinical features include active ocular inflammatory processes, hearing loss, arthritis, mucocutaneous manifestations, laboratory and major events such as death and adverse effects.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-08 18:01:07 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Studies were eligible if they fulfilled all of the following criteria: randomized controlled trials, single or double-blind. Open studies (with no blinding) were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with Behcet's syndrome as defined by the International Study Group (<LINK REF="REF-Int-Study-Group-1990" TYPE="REFERENCE">Int Study Group 1990</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Any pharmacological therapy compared to placebo or another pharmacological intervention for the treatment of Behcet's syndrome.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The outcomes assessed for this meta-analysis are:</P>
<P>1.- Active ocular inflammatory processes (uveitis, hypopyon)<BR/>Frequency, severity, remission, partial improvement, deterioration<BR/>Withdrawals due to eye disease<BR/>Development of new eye disease<BR/>Corticoid treatment of deteriorating eye disease<BR/>Visual acuity change<BR/>Involvement of previously unaffected eye</P>
<P>2.- Arthritis<BR/>Number of arthritis attacks per person.<BR/>Number of episodes of arthritis attacks per group<BR/>Duration of episode<BR/>Severity of attack<BR/>Pattern of joint involvement<BR/>Necessity of corticosteroid treatment, either oral or enteral</P>
<P>3.- Mucocutaneous manifestations (oral ulcer, genital ulcer, erythema nodosum).<BR/>Frequency, number, duration, severity</P>
<P>4.- Laboratory changes in:<BR/>White cell counting (WCC)<BR/>C reactive protein (CRP)<BR/>Erythrocyte sedimentation rate (ESR)</P>
<P>5.- Hearing loss.<BR/>Change in dB hearing levels</P>
<P>6.- Major events such as adverse effects and death</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-08 18:01:07 -0500" MODIFIED_BY="[Empty name]">
<P>To identify trials of any pharmacological intervention versus either placebo or another pharmacological intervention for the management of the Behcet's syndrome, a search in the MEDLINE database was performed, from January 1966 to January 1998. The strategy used was the one developed by the Cochrane Collaboration, adopted and modified for the Cochrane Musculoskeletal Group (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>), as shown in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.<BR/>
<BR/>The reviewers processed the former 480 full references (authors, title, source, keywords, abstract, MeSH and keywords) to identify any potentially relevant articles. After discarding papers dealing with editorials, comments, reviews, either basic or animal research, diagnostics approach, follow-up studies, and case series, 27 references which included the words random, blinding, masking, trial or prospective study were initially included.</P>
<P>Two additional references were found in the Cochrane Controlled Trials Register (CCTR). The computer search was complemented by a hand search of all bibliographic references from the reference lists of included trials. Three additional references were included after this handsearching. Principal investigators were contacted to seek unpublished literature. All languages were included.</P>
<P>Finally, 32 references were included as potentially relevant.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>The Cochrane Controlled Trials Register (CCTR) will be searched for future updates.</P>
<P>The 32 potentially relevant references were assessed by two independent reviewers (MA, AS) according to five inclusion criteria: diagnosis of Behcet's syndrome, randomization, blinding, pharmacological treatment versus either placebo or another pharmacological treatment and measurement of a clinical outcome. Ten trials fit the inclusion criteria and were included in this review.</P>
<P>The 22 discarded references were excluded because they were: open studies (10 studies), follow-up studies (2), retrospective studies (2), uncontrolled (3), comments of a trial (2), patients with Behcet's syndrome included in a group with other non-Behcet's patients with uveitis and it was not possible to extract individual data (1), Behcet's patients were used to validate a questionnaire for Rheumatoid Arthritis (1) and a review of the disease (1). </P>
<P>Data extraction</P>
<P>From the 10 included trials, data were independently extracted by two observers (MA, AS) and cross-checked. The studies examined several different pharmacological interventions. In some cases two trials on the same intervention were found, but the data included different clinical outcomes, such as arthritis in one trial and mucocutaneous symptoms in another.</P>
<P>Because of the differences in interventions and outcomes across trials, it was not possible to pool data from different studies for any outcomes or interventions. This reflects a lack of standardization of outcomes measured for clinical trials examining Behcet's syndrome. It also demonstrates a need for further research, with standardized outcomes, so that larger numbers of patients are available for analysis.</P>
<P>To assess changes in disease activity, the following measurements were considered a priority: uveitis attacks, visual acuity changes, hearing changes, oral or genital ulcers count, swollen joint count, tender joint count, arthritis attacks and episodes per patient, episodes by group and pain.<BR/> <BR/>Statistical analysis: </P>
<P>Since the different pharmacological interventions could not be pooled, they were analyzed separately. For dichotomous measures, the treatment effect for each trial was calculated using a fixed effect model [Peto model (Petitti 1994)]. </P>
<P>The trials included in this review used different indices to evaluate changes in disease activity. For instance, different total numbers of joints were considered and assessments were measured with various scales. To enhance future comparability across trials all the continuous outcome variables were compared using standardized mean differences between intervention and placebo groups. The standardized mean differences were based, if available, on end-of-trial results.</P>
<P>One author (Ertenli) was contacted to determine if one trial (<LINK REF="STD-Calguneri-1996a" TYPE="STUDY">Calguneri 1996a</LINK>) was masked, as well as to seek unpublished studies. As of March 1998, we have not received a reply. The estimates were calculated using Revman 3.01. The analysis was conducted separately for each different intervention, for the reasons described previously.</P>
<P>Since the trials could not be pooled it was not possible to carry out a sensitivity analysis by quality scores or a subgroup analysis by drug dosages. Because of this lack of comparability across trials and the small number of trials, we could not conduct a heterogeneity test or a funnel plot.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>A total of 10 out of 32 potentially relevant references were included since they were randomized, controlled, single or double-blind trials (<LINK REF="STD-Aktulga-1980" TYPE="STUDY">Aktulga 1980</LINK>, <LINK REF="STD-Benamour-1991" TYPE="STUDY">Benamour 1991</LINK>, <LINK REF="STD-Benezra-1988" TYPE="STUDY">Benezra 1988</LINK>, <LINK REF="STD-Calguneri-1996a" TYPE="STUDY">Calguneri 1996a</LINK>, <LINK REF="STD-Davies-1988" TYPE="STUDY">Davies 1988</LINK>, <LINK REF="STD-Hamuryudan-1991" TYPE="STUDY">Hamuryudan 1991</LINK>, <LINK REF="STD-Masuda-1989" TYPE="STUDY">Masuda 1989</LINK>, <LINK REF="STD-Moral-1995" TYPE="STUDY">Moral 1995</LINK>, <LINK REF="STD-Oryazgan-1992" TYPE="STUDY">Oryazgan 1992</LINK>, <LINK REF="STD-Yacizi-1990" TYPE="STUDY">Yacizi 1990</LINK>). </P>
<P>All 10 RCTs included in the analysis assessed several clinical outcomes, some also reported side effects. In <LINK REF="STD-Yacizi-1990" TYPE="STUDY">Yacizi 1990</LINK>, one of the patients on placebo died due to Behcet's-related pulmonary vascular disease. No other cases of death were reported in these trials.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The quality of the included trials was assessed independently by two observers (MA, AS) using a validated scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). This scale consists of three items pertaining to the description of randomization, blinding, dropouts and withdrawals per group, as described in the report of a RCT. The scale ranges from zero to five (two points each for randomization and blinding and one point for the description of drop-outs and withdrawals per intervention group), with higher scores indicating superior reporting. Interobserver agreement was measured using a weighted kappa, an adjusted measure of agreement, removing contributions expected by chance. Values between 0.60-0.80 indicate substantial strength of agreement, higher than 0.81 is almost perfect (<LINK REF="REF-Landis-1977" TYPE="REFERENCE">Landis 1977</LINK>).</P>
<P>The interobserver agreement, before consensus, measured with kappa was equal to 0.71. Discussion resolved disagreements. The median quality score of the included trials was 3 (range 0-5).</P>
<P>The allocation concealment of the included trials was assessed independently by two observers (MA, AS). The allocation concealment was adequate in 2 trials, inadequate in 3 trials and unclear in 5 trials.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Ten trials out of 32 potentially relevant articles were included in this systematic review.</P>
<P>Overall, the included trials reported on 679 patients, of which 189 were randomized to a placebo group (22 patients from a cross-over design), 126 to colchicine, 104 to cyclosporine, 60 to colchicine plus benzathine-penicillin, 50 to a saliva autologue, 37 to azathioprine, 30 to azapropazone, 30 to topic alpha-interpheron, 22 to acyclovir (cross-over design), 20 to conventional therapy (steroids, leukeran) and 11 to cyclophosphamide. </P>
<P>The results of the studies are summarized by four main categories: eye involvement, oral and genital ulcers, dermic lesions and arthritis. No studies explored changes in hearing.</P>
<P>Eye involvement:</P>
<P>In <LINK REF="STD-Aktulga-1980" TYPE="STUDY">Aktulga 1980</LINK>, there were no differences in eye improvement between colchicine vs placebo with an odds ratio (OR) of 0.47 (95% CI: 0.06, 3.78). </P>
<P>In <LINK REF="STD-Benezra-1988" TYPE="STUDY">Benezra 1988</LINK> (cyclosporine vs conventional therapy), the authors report that most of the patients on cyclosporine demonstrated better visual acuity after treatment. However, there was no difference in visual acuity after 1 month between cyclosporine and conventional therapy [WMD 0.070, (95%CI, -0.117, 0.257)]. After two years of receiving cyclosporine, most patients continue to show stable or better visual acuity than baseline, but there was no difference between cyclosporine and conventional therapy [WMD 0.120, (95%CI, -0.163, 0.403)].</P>
<P>In <LINK REF="STD-Masuda-1989" TYPE="STUDY">Masuda 1989</LINK>, cyclosporine resulted in significantly more improvements than colchicine in the frequency (OR 0.10, 95%CI, 0.04, 0.23) and severity (OR 0.10, 95%CI, 0.04, 0.23) of ocular attacks (p&lt;0.001 according to the authors). Clinical symptoms were significantly better in the cyclosporine group than in colchicine with an OR of 0.11 (95%CI, 0.03, 0.40, p&lt;0.001).</P>
<P>In <LINK REF="STD-Oryazgan-1992" TYPE="STUDY">Oryazgan 1992</LINK>, (low dose cyclosporine vs cyclophosphamide) the mean dose of cyclosporine used was 4.89 mg/kg/day during the 6 months of the masked period. Visual acuity significantly improved (p&lt;.0001) when compared with that observed at entry, according to the authors. However, there was no difference between cyclosporine and cyclophosphamide [WMD 0.800 (95%CI, -2.521, 4.121]. This initial improvement however disappeared by the time the trial was unmasked. The visual acuity among the 8 patients continuing to use cyclosporine at the end of the 24 months remained approximately the same at the time of unmasking of the trial or at entry. No change in visual acuity among the patients using cyclophosphamide occurred at the three time points, apart from a trend to deterioration at the time of unmasking the trial when compared with that at the time of entry. Although there was a trend for fewer ocular attacks in the cyclosporine group, this did not reach statistical significance for the time intervals assessed with an WMD at 6 months of -0.140 (95%CI -0.350, 0.070) and 12 months [WMD -0.110 (95%CI -0.561, 0.341)].</P>
<P>In <LINK REF="STD-Yacizi-1990" TYPE="STUDY">Yacizi 1990</LINK>, (azathioprine vs placebo) there were two different groups: with and without previous eye involvement. In the group without previous eye involvement, 9 patients were diagnosed with eye disease during the trial, 8 of 13 receiving placebo and 1 out of 12 receiving azathioprine [OR 0.11 (95% CI, 0.02, 0.54), p=0.008 Fisher's exact test]. One patient receiving placebo required an injection of methylprednisolone to treat deteriorating eye disease.</P>
<P>In the group with previous eye involvement, 6 out of 23 patients receiving placebo were withdrawn because of severe eye disease compared to 0 of 25 azathioprine patients [OR 0.10 (95%CI, 0.02, 0.53). Fourteen patients had uniocular eye disease at the start of the trial, 7 receiving azathioprine and 7 placebo. In 5 in the placebo group and 0 in the azathioprine group, disease developed in the unaffected eye [OR 0.06 (95%CI, 0.01, 0.46, p&lt;0.001)].</P>
<P>Seven patients taking placebo had 15 episodes of hypopyon uveitis as compared with one taking azathioprine who had a single episode [OR 0.16 (95% CI, 0.03, 0.70). This reached statistical significance in the trial (p=0.018 Fisher's exact test)]. High dose methylprednisolone was required by 6 patients (with 9 episodes) taking azathioprine and 10 patients (with 16 episodes) taking placebo [OR 0.42 (95%CI, 0.13, 1.39)].</P>
<P>With data included on the six patients withdrawn from the trial because of severe eye disease, the mean visual acuity was unchanged between the first and last visits in the azathioprine group compared to a small but significant deterioration in visual acuity in the placebo group [WMD -0.910 (95% CI, -1.962, 0.142), p&lt;0.025]. The worsening in the placebo group was also evident when data on the six patients who were withdrawn were excluded from the analysis (p&lt;0.01).</P>
<P>Oral and genital ulcers :</P>
<P>In <LINK REF="STD-Aktulga-1980" TYPE="STUDY">Aktulga 1980</LINK>, there were no differences in aphtas [OR 3.01 (95%CI, 0.56, 16.15)] or genital ulcers [OR 2.30 (95% CI, 0.34, 15.44)] between colchicine and placebo groups . </P>
<P>In <LINK REF="STD-Benamour-1991" TYPE="STUDY">Benamour 1991</LINK>, (autologue saliva vs placebo) there were no differences in the severity of oral aphta [OR 1.36 (95% CI, 0.38, 4.87)] or genital ulcers [OR 1.19 (95% CI, 0.21, 6.61)].</P>
<P>In <LINK REF="STD-Davies-1988" TYPE="STUDY">Davies 1988</LINK>, there were no differences between acyclovir and placebo for the frequency of oral ulcers [WMD 3.3, (95%CI, -12.379, 18.979)] and genital ulcers [WMD 0.0 (95%CI, -9.283, 9.283)] during treatment (p=0.21 according to the authors).</P>
<P>In <LINK REF="STD-Hamuryudan-1991" TYPE="STUDY">Hamuryudan 1991</LINK>, the topical alpha-interpheron was inefficacious in the prevention of new ulcers [WMD = 2.90 (95% CI: -4.396, 10.196)] and did not decrease the absolute number of ulcers in the treatment group [WMD = 1.05 (95% CI: 0.082, 2.018)].</P>
<P>In <LINK REF="STD-Masuda-1989" TYPE="STUDY">Masuda 1989</LINK>, cyclosporine resulted in significantly more alleviation of oral aphtas ulcers versus colchicine [OR 0.14, (95% CI, 0.06, 0.31)]. Clinical symptoms were significantly improved in the cyclosporine group compared to the colchicine group [OR 0.11, (95% CI, 0.03, 0.40)].</P>
<P>Dermic lesions :</P>
<P>In <LINK REF="STD-Masuda-1989" TYPE="STUDY">Masuda 1989</LINK>, cyclosporine compared to colchicine alleviated dermal lesions [OR 0.30, (95% CI, 0.12, 0.75), p&lt;0.01].</P>
<P>Arthritis :</P>
<P>In <LINK REF="STD-Aktulga-1980" TYPE="STUDY">Aktulga 1980</LINK>, (colchicine vs placebo) there was no significant difference in arthritis improvement [OR 0.49, (95% CI, 0.05, 5.11)] or arthralgia improvement [OR 0.85, (95%CI 0.06, 11.78)].</P>
<P>In <LINK REF="STD-Calguneri-1996a" TYPE="STUDY">Calguneri 1996a</LINK>, (colchicine vs colchicine plus benzathine-penicillin) those in the colchicine-benzathine penicillin group had significantly less arthritis episodes compared to colchicine alone [OR 0.09, (95%CI, 0.05, 0.19)]. The subgroup analysis of patients with no history of arthritis revealed a significantly higher incidence of new arthritis episodes in colchicine vs combination therapy during the follow-up period [OR 0.19, (95% CI, 0.04, 0.85), p&lt;0.001).</P>
<P>In the same study, a log-rank test showed a significant increase in the median duration of episode-free periods (p&lt;0.001) in the penicillin-treated patients compared with those who received colchicine alone, i.e., 13.2 months (range 5-16.4 months) versus 7.4 months (range 2-16 months). We calculated the standard deviation using the range and Chebyshev's rule, and confirmed this statistical increase in the duration of episode-free periods with a WMD of 5.80 (95% CI, 4.608, 6.992). In contrast, there were no differences between the groups in terms of duration [OR -0.50 (95% CI: -2.449, 1.449)], severity [OR 0.73 (95% CI: 0.16, 3.38)], or pattern (OR 0.94 (95% CI: 0.10, 8.71)] of the arthritis episodes that did occur.</P>
<P>In <LINK REF="STD-Moral-1995" TYPE="STUDY">Moral 1995</LINK>, (azapropazone vs placebo), during the 3-week follow-up there were no significant differences between the two groups regarding the persistence of arthritis [OR 1.62, (95%CI, 0.58, 4.53)], the development of new attacks of arthritis [OR 0.61, (95%CI, 0.19, 1.98)] and the mean duration of arthritis [WMD 0.200, (95%CI, -4.085, 4.485)]. Joint swelling, the tender joint score and the visual analogue score improved significantly in both groups at all visits compared to the beginning of the trial, but there were no differences between groups on these parameters.</P>
<P>Laboratory markers:</P>
<P>In <LINK REF="STD-Yacizi-1990" TYPE="STUDY">Yacizi 1990</LINK>, (azathioprine vs placebo), there was no significant difference in white cell count (WCC) between groups [OR 2.78 (95% CI: 0.82, 9.42)].</P>
<P>In <LINK REF="STD-Moral-1995" TYPE="STUDY">Moral 1995</LINK>, (azapropazone vs placebo), there were no differences between groups at day 21 in mean C reactive protein (CRP) [WMD 1.0 (95% CI: -0.605, 2.605)] or erythrocyte sedimentation rate (ESR) [WMD 2.1 (95% CI: -11.277, 15.477)].</P>
<P>In <LINK REF="STD-Davies-1988" TYPE="STUDY">Davies 1988</LINK>, (acyclovir vs placebo), there were no differences between groups for WCC [WMD -0.1 (95% CI: -1.105, 0.905)], immunoglobin [WMD -0.10 (95% CI: -1.725, 1.525)], hemoglobin [WMD -0.10 (95% CI: -0.780, 0.580)] or ESR [WMD 4.60 (95% CI: -1.477, 10.677)].</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>The purpose of this study was to conduct a systematic review of pharmacological interventions versus either placebo or another pharmacological intervention for the treatment of the clinical features of the patients with the Behcet's syndrome.</P>
<P>Only studies contributing high evidence (RCTs) were reviewed. But clearly there is a lack in the performance of high methodological quality RCTs for this clinical condition. Including both double-blind trials (five) and single-blind trials (four), we include 10 studies to this review.</P>
<P>The allocation concealment was defined according to the definition of <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>. Only two RCTs had adequate allocation concealment and eight were inadequate or unclear.</P>
<P>Because of the lack of common interventions and/or lack of common outcomes across trials, none of the data could be pooled. Therefore, heterogeneity was not explored and it was not possible to carry out a sensitivity analysis, dealing with differences in the effect size depending on the quality of the trials or the dosage of drugs used.</P>
<P>It is useful to conduct a funnel-plot to explore the existence of publication bias in a meta-analysis. To do a funnel-plot, at least 5 or 6 trials on the same outcome and intervention are required. Since only one trial was available for each outcome and intervention combination, a funnel plot was not conducted.</P>
<P>The studies reviewed showed methodological problems that may threaten the validity of their results. In one of these studies (<LINK REF="STD-Benamour-1991" TYPE="STUDY">Benamour 1991</LINK>), 56% of the patients withdrew after randomization and before the intervention. For the final results, the intervention group comprised 30 patients and the placebo group 14. In <LINK REF="STD-Calguneri-1996a" TYPE="STUDY">Calguneri 1996a</LINK>, the study was described as single blind, but only the data analyst and main investigator were masked; the patients and physicians were not masked. In <LINK REF="STD-Oryazgan-1992" TYPE="STUDY">Oryazgan 1992</LINK>, only the ophtalmologist was masked.</P>
<P>In addition, several differences in the kind of interventions and described outcomes across trials were observed. Nine trials studied nine different pharmacological interventions for several different features of Behcet's syndrome. The former fact makes it impossible to pool data over either interventions or outcomes. This reflects an inconsistency in the selection and reporting of outcomes for trials evaluating therapy for Behcet's syndrome. This also demonstrates a need for more studies with either larger sample sizes or standardized outcomes so that a larger sample size is available for meta-analysis.</P>
<P>Because of the lack of comparability between studies, we had difficulty performing subgroup analyses. However, some authors conducted subgroup analyses that we have included. For example, <LINK REF="STD-Davies-1988" TYPE="STUDY">Davies 1988</LINK> divided the patients into those with and without previous eye involvement and <LINK REF="STD-Calguneri-1996a" TYPE="STUDY">Calguneri 1996a</LINK>, divided the patients in those with and without previous arthritis attacks.</P>
<P>Despite some positive results, this systematic review does not clearly support the therapeutic effect of any one of the studied interventions.</P>
<P>In the case of eye involvement, despite the small sample size (BenEzra 1988), visual acuity was maintained for those taking cyclosporine compared to worsening acuity for those receiving conventional therapy (corticoids, leukeran). These results were confirmed for cyclosporine vs colchicine by <LINK REF="STD-Masuda-1989" TYPE="STUDY">Masuda 1989</LINK>. In contrast, despite initial eye improvement in the cyclosporine group compared to cyclophosphamide in another trial (<LINK REF="STD-Oryazgan-1992" TYPE="STUDY">Oryazgan 1992</LINK>), the difference was not sustained after 2 years. In the trial of <LINK REF="STD-Yacizi-1990" TYPE="STUDY">Yacizi 1990</LINK> (azathioprine vs placebo), the patients on azathioprine with or without previous eye disease experienced significantly less eye involvement than placebo. However, the sample size was too small to generalize these results.</P>
<P>The trial that used benzathine-penicillin plus colchicine vs colchicine (<LINK REF="STD-Calguneri-1996a" TYPE="STUDY">Calguneri 1996a</LINK>) showed better results in the frequency of attacks of arthritis and new episodes of arthritis for benzathine-penicillin plus colchicine. However there were no differences between both groups in terms of duration, severity or pattern of the episodes of arthritis that did occur. Azapropazone showed no benefits for arthritis involvement in Behcet's syndrome when compared to a placebo (<LINK REF="STD-Moral-1995" TYPE="STUDY">Moral 1995</LINK>).</P>
<P>A concern with this systematic review is the potential existence of publication bias. Thus, it is desirable that future trials use better methodology in terms of masking, reporting the flow of the participants and standardizing the outcome measures. We encourage investigators to describe fully the numbers and flow of patients by treatment groups throughout the trial and to clearly report the reasons for dropouts from each group. This review was hampered by lack of uniformity in the way these items were reported. </P>
<P>In summary, the results of our review do not suggest clear advantages of some classic treatments for Behcet's syndrome such as colchicine (for eye involvement, aphtas, dermal lesions or arthritis), steroids (eye), azapropazone (arthritis) and acyclovir for aphtas. The results do suggest that cyclosporine and azathioprine are beneficial for the prevention of eye involvement, and that benzathine-penicillin helps prevent new attacks of arthritis.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Our results demonstrate the lack of efficacy of some of the classic treatments for Behcet's syndrome, including colchicine, cyclophosphamide and steroids for eye involvement, azapropazone and colchicine for arthritis and acyclovir and colchicine for aphtas.</P>
<P>The results confirm the protective effects of cyclosporine and azathioprine for eye involvement and benzathine-penicillin for arthritis.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Because of the lack of common interventions and common outcomes across trials, none of the included trials could be pooled. More randomized, placebo-controlled, double-blind trials should be carried out to compare cyclosporine, azathioprine and benzathine-penicillin vs placebo in order to make the results generalizable and comparable.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank Jessie McGowan from the Library of the Ottawa General Hospital for helping develop and implement the electronic search for this review. Many thanks to Dr. David Scott for his valuable editorial review of this manuscript.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS/>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-08 18:12:37 -0500" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Aktulga-1980" NAME="Aktulga 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun Y, et al. A double blind study of colchicine in behcet's disease. Haematologica (Pavia) 1980;65:399-402&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun Y, et al</AU>
<TI>A double blind study of colchicine in behcet's disease</TI>
<SO>Haematologica (Pavia)</SO>
<YR>1980</YR>
<VL>65</VL>
<PG>399-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benamour-1991" NAME="Benamour 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benamour S, Bennis R, Messoudi M, Zaoui A, Amor B</AU>
<TI>Desensibilisation a la salive autologue et maladie de Behcet</TI>
<SO>Rev Med Interne</SO>
<YR>1991</YR>
<VL>12</VL>
<PG>339-342</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benezra-1988" NAME="Benezra 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;BenEzra D, Cohen E, Chajek T, Friedman G, Pizanti S, Courten C de, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's Syndrome. Transplantation Proceedings 1988;20 (3) (Suppl 4):136-143.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>BenEzra D, Cohen E, Chajek T, Friedman G, Pizanti S, Courten C de, et al</AU>
<TI>Evaluation of conventional therapy versus cyclosporine A in Behcet's Syndrome</TI>
<SO>Transplantation Proceedings</SO>
<YR>1988</YR>
<VL>20</VL>
<NO>3</NO>
<PG>136-143</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Calguneri-1996a" NAME="Calguneri 1996a" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calguneri M (a), Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Celik I</AU>
<TI>The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with behcet's disease. A randomized clinical trial</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>2062-2065</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davies-1988" NAME="Davies 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davies UM, Palmer RG, Denman AM</AU>
<TI>Treatment with acyclovir does not affect orogenital ulcers in Behcet's syndrome: a randomized double-blind trial</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1988</YR>
<VL>27</VL>
<PG>300-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamuryudan-1991" NAME="Hamuryudan 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Hamuryudan V, Yurdakul S, Rosenkaimer F, Yazici H. Inefficacy of topical alpha interferon in the treatment of oral ulcers of Behcet's syndrome: a randomized, double blind trial [letter]. British Journal of Rheumatology 1991; 30:395-396.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamuryudan V, Yurdakul S, Rosenkaimer F, Yazici H</AU>
<TI>Inefficacy of topical alpha interferon in the treatment of oral ulcers of Behcet's syndrome: a randomized, double blind trial [letter]</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1991</YR>
<VL>30</VL>
<PG>395-396</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masuda-1989" NAME="Masuda 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G</AU>
<TI>Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>1</VL>
<PG>1093-1096</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moral-1995" NAME="Moral 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moral F, Hamuryudan V, Yurdakul S, Yacizi H</AU>
<TI>Inefficacy of azapropazone in the acute arthritis of Behcet's syndrome: a randomized, double blind, placebo controlled study</TI>
<SO>Clinical &amp; Experimental Rheumatology</SO>
<YR>1995</YR>
<VL>13</VL>
<PG>493-495</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oryazgan-1992" NAME="Oryazgan 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ozyazgan Y, Yurdakul S, Yacizi H, Tuzun B, Iscimen A, Tuzun Y, et al</AU>
<TI>Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial</TI>
<SO>British Journal of Ophtalmology</SO>
<YR>1992</YR>
<VL>76</VL>
<PG>241-243</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yacizi-1990" NAME="Yacizi 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yacizi H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, et al</AU>
<TI>A controlled trial of azathioprine in Behcet's syndrome</TI>
<SO>New England Journal of Medicine</SO>
<YR>1990</YR>
<VL>322</VL>
<PG>281-285</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Abdalla-1973" NAME="Abdalla 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abdalla MI</AU>
<TI>Long-lasting remission of Behcet's disease after chlorambucil therapy</TI>
<SO>Br-J-Ophtalmol</SO>
<YR>1973</YR>
<VL>57</VL>
<PG>706-711</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bach-1997" NAME="Bach 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Bach JF. Tolerance and uveitis. Editorial. Am J Ophtalmol 1997; 123:684-687.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bach JF</AU>
<TI>Tolerance and uveitis. Editorial</TI>
<SO>Am J Ophtalmol</SO>
<YR>1997</YR>
<VL>123</VL>
<PG>684-687</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chavis-1992" NAME="Chavis 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Chavis PS, Antonios SR, Tabbara KF. Cyclosporine effects on optic nerve and retinal vasculitis in Behcet's disease. Documenta Ophthalmologica 1992; 80:133-142.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chavis PS, Antonios SR, Tabbara KF</AU>
<TI>Cyclosporine effects on optic nerve and retinal vasculitis in Behcet's disease</TI>
<SO>Documenta Ophthalmologica</SO>
<YR>1992</YR>
<VL>80</VL>
<PG>133-142</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elidan-1991" NAME="Elidan 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elidan J, Levi H, Cohen E, Benezra D</AU>
<TI>Effect of cyclosporine A on the hearing loss in Behcet's disease</TI>
<SO>Annals of Otology, Rhinology &amp; Laryngology</SO>
<YR>1991</YR>
<VL>100</VL>
<PG>464-468</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gardner_x002d_Medwin-1994" NAME="Gardner-Medwin 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gardner-Medwin JM, Smith NJ, Powell RJ</AU>
<TI>Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1994</YR>
<VL>53</VL>
<PG>828-832</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamuryudan-1990" NAME="Hamuryudan 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamuryudan V, Yurdakul S, Serdaroglu S, Tuzun Y, Rosenkaimer F, Yazici H</AU>
<TI>Topical alpha interpheron in the treatment of oral ulcers in Behcet's syndrome: a preliminary report</TI>
<SO>Clinical &amp; Experimental Rheumatology</SO>
<YR>1990</YR>
<VL>8</VL>
<PG>51-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamuryudan-1994" NAME="Hamuryudan 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamuryudan V (b), Moral F, Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, et al</AU>
<TI>Systemic Interpheron alpha 2b treatment in Behect's syndrome</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1994</YR>
<VL>21</VL>
<PG>1098-1100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamuryudan-1997" NAME="Hamuryudan 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, Tuzun Y, et al</AU>
<TI>Azathioprine in Behcet's syndrome: effects on long-term prognosis</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1997</YR>
<VL>40</VL>
<PG>769-774</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ince-1996" NAME="Ince 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ince A, Yacizi Y, Hamuryudan V, Yacizi H</AU>
<TI>The frequency and clinical characterisitcs of methotrxate (MTX) oral toxicity in rheumatoid arthritis (RA): a masked and controlled study</TI>
<SO>Clinical Rheumatology</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>491-494</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kazokoglu-1991" NAME="Kazokoglu 1991" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kazokoglu H, Saatci O, Cuhadaroglu H, Eldem B</AU>
<TI>Long-term effects of cyclophosphamide and colchicine treatment in behcet's disease</TI>
<SO>Ann Ophtalmol</SO>
<YR>1991</YR>
<VL>23</VL>
<PG>148-151</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mochizuki-1991" NAME="Mochizuki 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mochizuki M, Masuda K, Sakane T, Inaba G, Ito K, Kogure M, et al</AU>
<TI>A multicenter clinical open trial of FK506 in refractory uveitis, including Behcet's disease. Japanese FK 506 Study Group on refractory Uveitis</TI>
<SO>Transplantation Proceedings</SO>
<YR>1991</YR>
<VL>23</VL>
<PG>3343-3346</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nussenblatt-1983a" NAME="Nussenblatt 1983a" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Nussenblatt RB, Palestine AG, Chan CC. Cyclosporine Therapy in the treatment of intraocular inflammatory disease resistant to systemic steroids and cytotoxic agents. Am J Ophtalmol 1983; 96:275-282.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nussenblatt RB, Palestine AG, Chan CC</AU>
<TI>Cyclosporine Therapy in the treatment of intraocular inflammatory disease resistant to systemic steroids and cytotoxic agents</TI>
<SO>Am J Ophtalmol</SO>
<YR>1983</YR>
<VL>96</VL>
<PG>275-282</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nussenblatt-1983b" NAME="Nussenblatt 1983b" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Nussenblatt RB, Palestine AG, Rook AH, Scher I, Wacker BW. Treatment of intraocular inflammatory disease with cyclosporine A. Lancet 1983; ii:235-238.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nussenblatt RB, Palestine AG, Rook AH, Scher I, Wacker BW</AU>
<TI>Treatment of intraocular inflammatory disease with cyclosporine A</TI>
<SO>Lancet</SO>
<YR>1983</YR>
<VL>ii</VL>
<PG>235-238</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nussenblatt-1985a" NAME="Nussenblatt 1985a" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nussenblatt (a), Palestine AG, Chi-Chao Ch, Mochizuki M, Yancey K</AU>
<TI>Effectiveness of cyclosporin therapy for Behcet's disease</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1985</YR>
<VL>28</VL>
<PG>671-679</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nussenblatt-1985b" NAME="Nussenblatt 1985b" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nussenblatt RB, Palestine AG, Chan CC</AU>
<TI>Cyclosporine therapy for uveitis: long-term follow-up</TI>
<SO>Journal of Ocular Pharmacology</SO>
<YR>1985</YR>
<VL>1</VL>
<PG>369-382</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nussenblatt-1996" NAME="Nussenblatt 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nussenblatt RB, Whitcup SM, de SD, Caspi RR, Kozhich AT, Weiner HL, et al</AU>
<TI>Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. [Review]</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1996</YR>
<VL>778</VL>
<PG>325-337</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nussenblatt-1997" NAME="Nussenblatt 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Nussenblatt RB, Gery I, Weiner HL, Ferris FL, shiloach J, Remaley N, et al. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. American Journal of Ophthalmology 1997; 123:583-592.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nussenblatt RB, Gery I, Weiner HL, Ferris FL, shiloach J, Remaley N, et al</AU>
<TI>Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1997</YR>
<VL>123</VL>
<PG>583-592</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sakane-1995" NAME="Sakane 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sakane T, Mochizuki M, Inaba G, Masuda K</AU>
<TI>[A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behcet's disease and allied conditions]</TI>
<SO>Ryumachi</SO>
<YR>1995</YR>
<VL>35</VL>
<PG>802-813</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simsek-1991" NAME="Simsek 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simsek H, Dundar S, Telatar H</AU>
<TI>Treatment of Behcet's disease with indomethacin</TI>
<SO>International Journal of Dermatology</SO>
<YR>1991</YR>
<VL>30</VL>
<PG>54-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wechsler-1988" NAME="Wechsler 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wechsler B, Huong LT, Godeau P</AU>
<TI>Traitement Medical de la Maladie de Behcet</TI>
<SO>Journal des Maladies Vasculaires (Paris)</SO>
<YR>1988</YR>
<VL>13</VL>
<PG>262-269</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whitcup-1994" NAME="Whitcup 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whitcup SM, Salvo EJ, Nussenblatt RB</AU>
<TI>Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease</TI>
<SO>American Journal of Ophtalmology</SO>
<YR>1994</YR>
<VL>118</VL>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Calguneri-1996b" NAME="Calguneri 1996b" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calguneri M (b), Ertenli I, Kiraz S, Erman M, Celik I</AU>
<TI>Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet's disease</TI>
<SO>Dermatology</SO>
<YR>1996</YR>
<VL>192</VL>
<PG>125-128</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-08 18:12:37 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-08 18:12:37 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Cho-1996" MODIFIED="2008-11-08 18:05:32 -0500" MODIFIED_BY="[Empty name]" NAME="Cho 1996" TYPE="JOURNAL_ARTICLE">
<AU>Cho MK, Bero LA</AU>
<TI>The quality of drug studies published in symposium proceedings</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1996</YR>
<VL>124</VL>
<PG>485-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2008-11-08 18:11:56 -0500" MODIFIED_BY="[Empty name]" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Int-Study-Group-1990" MODIFIED="2008-11-08 18:12:02 -0500" MODIFIED_BY="[Empty name]" NAME="Int Study Group 1990" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. [Review] [16 refs]</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>335</VL>
<PG>1078-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-11-08 18:12:11 -0500" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Landis-1977" MODIFIED="2008-11-08 18:12:19 -0500" MODIFIED_BY="[Empty name]" NAME="Landis 1977" TYPE="JOURNAL_ARTICLE">
<AU>Landis R, Koch G</AU>
<TI>The measurement of observer agreement for categorical data</TI>
<SO>Biometrics</SO>
<YR>1977</YR>
<VL>33</VL>
<PG>159-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moutsopoulos-1994" MODIFIED="2008-11-08 18:12:28 -0500" MODIFIED_BY="[Empty name]" NAME="Moutsopoulos 1994" TYPE="BOOK_SECTION">
<AU>Moutsopoulos, HM</AU>
<TI>Chapter 2.90: Behcet's Syndrome</TI>
<SO>Harrison's Principles of Internal Medicine</SO>
<YR>1994</YR>
<EN>13th</EN>
<ED>Isselbacher KJ, Brunwald E, Wilson JD et al</ED>
<PB>McGraw-Hill</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-11-08 18:12:37 -0500" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Aktulga-1980">
<CHAR_METHODS>
<P>Randomized, placebo-controlled, double-blind trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Thirty-five patients with Behcet's disease (O'Duffy criteria). <BR/>Twenty-four weeks trial<BR/>Male /female ratio 3.6<BR/>Analysis exclude drop-outs (4 and 3)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Placebo (n=17) or colchicine 0.5 mg t.i.d.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessment of aphtas<BR/>Eye involvement<BR/>Genital ulcers<BR/>Erythema nodosum<BR/>Pyoderma<BR/>Arthritis<BR/>Arthralgia.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score=3<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Benamour-1991">
<CHAR_METHODS>
<P>Randomized, placebo-controlled, single-blind trial. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>One hundred patients with Behcet's syndrome with either oral or genital aphtas and joint involvement were included in a 15 week trial. <BR/>Exclusion criteria: patients on immunosupressants or on corticoids. <BR/>There were no differences pre-trial except for the presence of joint lesion (intervention 73%, placebo 57%).<BR/>Fifty-six withdrawals before intervention.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Five intradermal injections per week (after 5th week two injections per week) of progressively diluted (from 1/10 000 000 to 1/100 in a period of 5 weeks) autologous saliva (n=30) or physiological serum (n=14).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rate of improvement of oral and genital aphtas<BR/>Joint involvement.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score=3<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Benezra-1988">
<CHAR_METHODS>
<P>Randomized, controlled, single-blind trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Forty patients with ocular Behcet's syndrome were included in a 104 weeks trial.<BR/>No clear statement of inclusion/exclusion criteria.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cyclosporin A 10 mg/kg/d was tapered to 5 mg/kg/d (n=20) or conventional therapy: (n=20) 1 to 1.5 mg prednisolone/kg/d or chlorambucil 0.1-0.2 mg/kg/d and the dosage was lowered according to clinical response.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Visual acuity, mouth ulcers, genital ulcers. Patients drop-outs because severity of eye involvement.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score=2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Calguneri-1996a">
<CHAR_METHODS>
<P>Randomized, controlled, single-blind (data analyst and the independent investigator) clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Hundred and twenty patients (1.07 male/female ratio) were included in a 104 week trial.<BR/>Inclusion criteria: Int. Study Group.<BR/>No significant differences between groups pre-trial.<BR/>Mean age 36.8 sd 9.6<BR/>Intention to treat analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Colchicine 1.5 mg/day (n=60) or colchicine plus intramuscular benzatine-penicilline 1.2 million ui/3 weeks (n=60).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Arthritis: incidence, duration, severity and pattern of attacks. <BR/>Co-interventions: corticoids.<BR/>Duration of arthritis episode-free periods. <BR/>Subgroup analysis: patients with no prior history of arthritis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score=2<BR/>Neither dropouts nor withdrawals.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Davies-1988">
<CHAR_METHODS>
<P>Randomized, placebo-controlled, double-blind, clinical trial. Crossover design.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Twenty-two patients with recurrent oral and genital ulceration (Mason and Barnes criteria for Behcet's syndrome) were included in a 24 week trial.<BR/>Patients with life-threatening or severe complications such as active uveitis were excluded. <BR/>Mean age 43 (range 18-55 years). <BR/>Males/women 7/15.<BR/>Drop-outs: two patients on active treatement, one because unacceptably active disease. Four withdrawals.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Acyclovir (n=22) (4000 mg/day/1 week, followed by 800 mg daily for 11 weeks) or placebo (n= 22). Four weeks of washout and they crossed to the missed intervention for an additional period of 12 weeks. <BR/>Six patients were on corticoids, one on azathioprine, and a second aspirin, during the whole trial.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Frequency of oral ulcers, new lesions. <BR/>Frequency of genital ulcers, new lesions. <BR/>ESR, Hb, WBC, IgG.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score=5<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hamuryudan-1991">
<CHAR_METHODS>
<P>Randomized, placebo-controlled, double-blind trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Sixty-three behcet's patients (26 males, 37 females) with active oral ulcers were included in a 24-week trial. Two withdrawals (1/1).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Topical Interpheron-alpha-2c hydrogel (1*10^5 U/g) qid (n=30) vs placebo (n=31).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>New ulcers, total ulcers.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score=3.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Masuda-1989">
<CHAR_METHODS>
<P>Randomized, controlled, double-blind trial. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Ninety-six patients aged 15 years or more with Behcet's syndrome, whose visual acuity was 20/40 or less, and who experienced at least two episodes of ocular attack during the prior 16 weeks, were included in a 16 weeks trial. <BR/>There were no significant differences between the two groups pre-trial.<BR/>Dropouts: renal dysfunction in 1 cyclosporin case and hepatic dysfunction in two colchicine cases.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cyclosporin 10 mg/kg/day (n=47) or colchicine 1 mg/day (n=46).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Frequency of ocular attack<BR/>Visual acuity<BR/>Ocular manifestations<BR/>Systemic symptoms.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score=3<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Moral-1995">
<CHAR_METHODS>
<P>Randomized, placebo-controlled, double-blind clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Sixty-three Behcet's patients with acute arthritis of up to 10 days of duration were included in a 3 weeks trial. Twenty-eight patients (14 males, 14 females; mean age 36.2 sd 8.1 years) from azapropazone, and 29 patients (18 males, 11 females; mean age 34.2 sd 8.4 years) from the placebo completed the trial. <BR/>Exclusion: patients on NSAID and those with contraindication to NSAID.<BR/>No dropouts.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Azapropazone 300 mg or placebo qid. Use of acetaminophen was allowed and the number of tablets recorded. Six patients were on azathioprine (3 / 3), and 11 (6 AZP / 5 PBO) were on colchicine, during the trial.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Persistence of Arthritis<BR/>New Arthritis<BR/>Mean episode duration<BR/>Joint swelling<BR/>Tender joint score<BR/>Visual analogue scale for pain<BR/>Mean CRP mg/dl<BR/>Mean ESR, mm/hour.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score=3 <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Oryazgan-1992">
<CHAR_METHODS>
<P>Randomized, controlled, single-mask (the ophthalmological examination) clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Twenty-three patients with Behcet's syndrome and bilateral, severe, reversible uveitis with posterior involvement and at least three ocular disease attacks within the previous 6 months were included in a 104 week trial, of them a mean of 52 weeks masked. <BR/>Exclusion: end stage disease, irreversible retinal damage, blindness, on immunosupressive agents. <BR/>No pre-treatment differences between groups except for sex.<BR/>Women did not accept to be included in Cyc A group because risk of hirsutism. <BR/>Mean age 29 sd 6 (Cyc A), mean 32 sd 6 (CTX). <BR/>Mean visual acuity at entry 4.46 sd 2.96 (Cyc A) 4.77 2.65 (CTX). <BR/>Duration of eye disease in years 2.64 sd 1.58 (Cyc A), 2.39 sd 2.37 (CTX).<BR/>No dropouts.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral cyclosporin A 5 mg/kg/day (n=12) or monthly intravenous 1 g boluses of cyclophosphamide (n=11). <BR/>Three patients were on corticoids during the trial (1/2).<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Improvement of visual acuity<BR/>Incidence of ocular attacks/patient/month</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score=0<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yacizi-1990">
<CHAR_METHODS>
<P>Randomized, placebo-controlled, double-blind clinical trial. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>O'Duffy's criteria for diagnosis of Behcet's syndrome<BR/>Exclusion: irreversible bilateral eye disease, fundi not assessable, those on immunosupressive agents, levamisole or penicillamine in the previous 3 months or corticoids in the last month. Group I: under 40 years, whose duration of disease was 24 months or less, without evidence of uveitis (n=25), and group II: patients of any age and any duration of the disease with eye disease (n=48), were included in a 104 week trial.<BR/>Dropouts: 6 in the group 2 on placebo, because of severe eye disease. Intention to treat analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group I: azathioprine 2.5 mg/kg (n=12) or placebo (n=13) and group II: azathioprine 2.5 mg/kg (n=25) or placebo (n=23). Corticosteroid treatment remained available to all patients.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Azathioprine effect on preexisting eye disease and prevention of new eye disease Withdrawals due to eye disease<BR/>Development of new eye disease<BR/>Involvement of previously unaffected eye<BR/>Hypopyon uveitis<BR/>Corticosteroid treatment of deteriorating eye disease<BR/>Change in visual acuity<BR/>Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score=3<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Abdalla-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bach-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Editorial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chavis-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elidan-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gardner_x002d_Medwin-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hamuryudan-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hamuryudan-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hamuryudan-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Follow-up of Yacizi 1990.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ince-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>To assess toxicity of methotrexate in rheumatoid arthritis patients, a questionnaire was used. To test its credibility it was tested in four different groups of patients. One of them was a Behcet's patient.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kazokoglu-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mochizuki-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nussenblatt-1983a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nussenblatt-1983b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nussenblatt-1985a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Follow-up.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nussenblatt-1985b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Follow-up.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nussenblatt-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pilot study. Not controlled. Two patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nussenblatt-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Forty patients with uveitis were included in the trial, but only seven with Behcet's syndrome. No characteristics, withdrawals or outcomes are isolated and available for the Behcet's syndrome patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sakane-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simsek-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wechsler-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Whitcup-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Calguneri-1996b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Aktulga-1980">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Benamour-1991">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Benezra-1988">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Calguneri-1996a">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Davies-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hamuryudan-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Masuda-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Moral-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Oryazgan-1992">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yacizi-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-11-08 18:04:03 -0500" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-11-08 18:03:26 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Azathioprine vs Placebo. No previous eye involvement.</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Necessitating withdrawal</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="138431" O_E="0.0" SE="0.0" STUDY_ID="STD-Yacizi-1990" TOTAL_1="12" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.5404816090424261" CI_START="0.021961463614374108" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.10894846116959897" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.2672190791894461" LOG_CI_START="-1.6583387198474082" LOG_EFFECT_SIZE="-0.9627788995184271" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.006668920661831656" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.00000000000001" Z="2.7129398694115467">
<NAME>New eye disease</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5404816090424263" CI_START="0.0219614636143741" EFFECT_SIZE="0.10894846116959897" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.267219079189446" LOG_CI_START="-1.6583387198474084" LOG_EFFECT_SIZE="-0.9627788995184271" ORDER="138432" O_E="-3.3200000000000003" SE="0.8171505630757668" STUDY_ID="STD-Yacizi-1990" TOTAL_1="12" TOTAL_2="13" VAR="1.4975999999999998" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-08 18:03:26 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Hypopyon uveitis</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="138433" O_E="0.0" SE="0.0" STUDY_ID="STD-Yacizi-1990" TOTAL_1="12" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.388987798756325" CI_START="0.0028910237446328644" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.1461565570715425" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.8685849494201575" LOG_CI_START="-2.5389483413557414" LOG_EFFECT_SIZE="-0.835181695967792" METHOD="PETO" MODIFIED="2008-11-08 18:03:26 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.3366683796206589" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.9607689228305228">
<NAME>Pulsed intravenous corticosteroid treatment</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.388987798756325" CI_START="0.0028910237446328644" EFFECT_SIZE="0.1461565570715425" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8685849494201575" LOG_CI_START="-2.5389483413557414" LOG_EFFECT_SIZE="-0.835181695967792" ORDER="138434" O_E="-0.48" SE="2.001601922563589" STUDY_ID="STD-Yacizi-1990" TOTAL_1="12" TOTAL_2="13" VAR="0.2496" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-08 18:03:26 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Oral corticosteroid treatment</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="138435" O_E="0.0" SE="0.0" STUDY_ID="STD-Yacizi-1990" TOTAL_1="12" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Azathioprine vs Placebo. Previous eye involvement.</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.5267390214202562" CI_START="0.01777864279953655" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0967714054378057" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.2784045074261545" LOG_CI_START="-1.7501013956250588" LOG_EFFECT_SIZE="-1.0142529515256065" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.006902615891450955" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="2.701506366078513">
<NAME>Necessitating withdrawal.</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5267390214202562" CI_START="0.01777864279953655" EFFECT_SIZE="0.0967714054378057" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="-0.2784045074261545" LOG_CI_START="-1.7501013956250588" LOG_EFFECT_SIZE="-1.0142529515256065" ORDER="138436" O_E="-3.125" SE="0.8644820371451241" STUDY_ID="STD-Yacizi-1990" TOTAL_1="25" TOTAL_2="23" VAR="1.3380984042553195" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.45749427281152627" CI_START="0.006766394764553761" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.05563799827784281" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.33961433832304017" LOG_CI_START="-2.1696426682290815" LOG_EFFECT_SIZE="-1.254628503276061" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.0072006510446334816" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0" Z="2.68741924943285">
<NAME>New eye disease.</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.45749427281152627" CI_START="0.006766394764553761" EFFECT_SIZE="0.05563799827784281" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.33961433832304017" LOG_CI_START="-2.1696426682290815" LOG_EFFECT_SIZE="-1.254628503276061" ORDER="138437" O_E="-2.5" SE="1.0749676997731399" STUDY_ID="STD-Yacizi-1990" TOTAL_1="7" TOTAL_2="7" VAR="0.8653846153846154" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6397167626354426" CI_START="0.016318525785477777" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.10217257208502115" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.19401226922194742" LOG_CI_START="-1.7873190779443537" LOG_EFFECT_SIZE="-0.9906656735831504" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.014798131991327894" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="2.437282048019385">
<NAME>Involvement of previously unaffected eye.</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6397167626354425" CI_START="0.016318525785477794" EFFECT_SIZE="0.10217257208502115" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.1940122692219475" LOG_CI_START="-1.787319077944353" LOG_EFFECT_SIZE="-0.9906656735831504" ORDER="138438" O_E="-2.6041666666666665" SE="0.9359163064394441" STUDY_ID="STD-Yacizi-1990" TOTAL_1="25" TOTAL_2="23" VAR="1.141631575059102" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6976327501435194" CI_START="0.03448461876636611" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.1551051237955433" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.15637313978312264" LOG_CI_START="-1.4623745708517455" LOG_EFFECT_SIZE="-0.8093738553174341" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.015127435743107829" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="2.4293137338333444">
<NAME>Hypopyon uveitis</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6976327501435194" CI_START="0.03448461876636611" EFFECT_SIZE="0.1551051237955433" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.15637313978312264" LOG_CI_START="-1.4623745708517455" LOG_EFFECT_SIZE="-0.8093738553174341" ORDER="138439" O_E="-3.166666666666667" SE="0.7671517054210559" STUDY_ID="STD-Yacizi-1990" TOTAL_1="25" TOTAL_2="23" VAR="1.6991725768321517" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3915680022639698" CI_START="0.12912776871079296" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4238986566877537" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.14350443401636942" LOG_CI_START="-0.8889803533876905" LOG_EFFECT_SIZE="-0.37273795968566054" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.15702874939769718" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="1.4151355750076295">
<NAME>Pulsed intravenous corticosteroid treatment.</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3915680022639698" CI_START="0.12912776871079296" EFFECT_SIZE="0.4238986566877537" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.14350443401636942" LOG_CI_START="-0.8889803533876905" LOG_EFFECT_SIZE="-0.37273795968566054" ORDER="138440" O_E="-2.333333333333334" SE="0.6064866750032697" STUDY_ID="STD-Yacizi-1990" TOTAL_1="25" TOTAL_2="23" VAR="2.7186761229314427" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5360429148502996" CI_START="0.039182896834406525" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.24532959679949007" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.1864033494339823" LOG_CI_START="-1.4069034592884235" LOG_EFFECT_SIZE="-0.6102500549272207" METHOD="PETO" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.1332609896389858" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="23" WEIGHT="100.0" Z="1.5013657415799415">
<NAME>Oral Corticosteroid treatment.</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5360429148502992" CI_START="0.039182896834406525" EFFECT_SIZE="0.24532959679949007" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.18640334943398218" LOG_CI_START="-1.4069034592884235" LOG_EFFECT_SIZE="-0.6102500549272207" ORDER="138441" O_E="-1.6041666666666665" SE="0.9359163064394441" STUDY_ID="STD-Yacizi-1990" TOTAL_1="25" TOTAL_2="23" VAR="1.141631575059102" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Azathioprine vs placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.14208315144552575" CI_START="-1.9620831514455257" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.91" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.09002381268721682" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="1.6952721117916298">
<NAME>Visual acuity [first minus last visit] mean sd</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.14208315144552575" CI_START="-1.9620831514455257" EFFECT_SIZE="-0.91" ESTIMABLE="YES" MEAN_1="0.17" MEAN_2="1.08" ORDER="138442" SD_1="1.39" SD_2="2.59" SE="0.5367869816712059" STUDY_ID="STD-Yacizi-1990" TOTAL_1="34" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.790050376483662" CI_START="1.0551463742740441" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.3743235297827887" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="105" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.2528652532821363" LOG_CI_START="0.02331271094175998" LOG_EFFECT_SIZE="0.13808898211194814" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.018370681352112637" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="782" TOTAL_2="612" WEIGHT="100.0" Z="2.358060850399122">
<NAME>GI side effects</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.790050376483662" CI_START="1.0551463742740441" EFFECT_SIZE="1.3743235297827887" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="105" LOG_CI_END="0.2528652532821363" LOG_CI_START="0.02331271094175998" LOG_EFFECT_SIZE="0.13808898211194814" ORDER="138443" O_E="17.48780487804879" SE="0.13484029967414773" STUDY_ID="STD-Yacizi-1990" TOTAL_1="782" TOTAL_2="612" VAR="54.99973309224802" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.415167819749016" CI_START="0.8231467336029721" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.783893790565692" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.973828065461701" LOG_CI_START="-0.08452274083402239" LOG_EFFECT_SIZE="0.44465266231383926" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.09957695771898692" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="23" WEIGHT="100.0" Z="1.6469079979544345">
<NAME>Low WCC (&lt;4,000/ml)</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.415167819749012" CI_START="0.8231467336029722" EFFECT_SIZE="2.783893790565692" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.9738280654617008" LOG_CI_START="-0.08452274083402234" LOG_EFFECT_SIZE="0.44465266231383926" ORDER="138444" O_E="2.6491228070175445" SE="0.6216805025390911" STUDY_ID="STD-Yacizi-1990" TOTAL_1="34" TOTAL_2="23" VAR="2.5874115112342255" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6875669352116052" CI_START="0.10410151844867147" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.2675383374221859" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-0.16268501651148193" LOG_CI_START="-0.9825429357241461" LOG_EFFECT_SIZE="-0.5726139761178141" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.0061852015501798795" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="36" WEIGHT="100.0" Z="2.737798206091557">
<NAME>IV steroids neccessity</NAME>
<GROUP_LABEL_1>Azathioprine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Azathioprine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6875669352116052" CI_START="0.10410151844867147" EFFECT_SIZE="0.2675383374221859" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.16268501651148193" LOG_CI_START="-0.9825429357241461" LOG_EFFECT_SIZE="-0.5726139761178141" ORDER="138445" O_E="-5.684931506849315" SE="0.48158860010767146" STUDY_ID="STD-Yacizi-1990" TOTAL_1="37" TOTAL_2="36" VAR="4.311690748733346" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2008-11-08 18:03:37 -0500" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Colchicine plus Benzathine Penicillin vs Colchicine. Arthritis</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.18832959459448353" CI_START="0.04524183425574793" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.09230588444999499" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-0.7250814284742171" LOG_CI_START="-1.3444597956342714" LOG_EFFECT_SIZE="-1.0347706120542441" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="5.797541238677384E-11" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0" Z="6.5488665391592535">
<NAME>Incidence of arthritis episodes</NAME>
<GROUP_LABEL_1>Col+Ben-Pen</GROUP_LABEL_1>
<GROUP_LABEL_2>Colchcine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Col+Ben</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours colchicine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.18832959459448353" CI_START="0.04524183425574793" EFFECT_SIZE="0.09230588444999499" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="49" LOG_CI_END="-0.7250814284742171" LOG_CI_START="-1.3444597956342714" LOG_EFFECT_SIZE="-1.0347706120542441" ORDER="138446" O_E="-18.0" SE="0.36382591884218074" STUDY_ID="STD-Calguneri-1996a" TOTAL_1="60" TOTAL_2="60" VAR="7.554621848739495" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.029724917587659716" CI_END="0.4168737987729062" CI_START="0.10632936202018375" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.21053722964467253" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-0.37999540016258415" LOG_CI_START="-0.9733467918969151" LOG_EFFECT_SIZE="-0.6766710960297496" METHOD="PETO" NO="2" P_CHI2="0.8631159073554395" P_Q="0.8631159073554395" P_Z="7.808335204795094E-6" Q="0.029724917587659716" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="84" WEIGHT="200.0" Z="4.470372855184515">
<NAME>Patients with arthritis episodes</NAME>
<GROUP_LABEL_1>Col+Ben-Pen</GROUP_LABEL_1>
<GROUP_LABEL_2>Colchcine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Col+Ben</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours colchicine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8462654511595538" CI_START="0.04133283170069474" DF="0.0" EFFECT_SIZE="0.18702552624412083" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="-0.0724933888626943" LOG_CI_START="-1.3837048403060292" LOG_EFFECT_SIZE="-0.7280991145843618" NO="1" P_CHI2="1.0" P_Z="0.029503976574952365" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="24" WEIGHT="100.0" Z="2.1766863615933305">
<NAME>Arthritis episodes in patients without prior history of arthritis</NAME>
<DICH_DATA CI_END="0.8462654511595538" CI_START="0.04133283170069474" EFFECT_SIZE="0.18702552624412083" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.0724933888626943" LOG_CI_START="-1.3837048403060292" LOG_EFFECT_SIZE="-0.7280991145843618" ORDER="138447" O_E="-2.8260869565217392" SE="0.7702120971791786" STUDY_ID="STD-Calguneri-1996a" TOTAL_1="22" TOTAL_2="24" VAR="1.6856962822936357" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.46693882508580975" CI_START="0.10089832547827349" DF="0.0" EFFECT_SIZE="0.21705608849316035" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="29" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="-0.33074001379781853" LOG_CI_START="-0.9961160413109613" LOG_EFFECT_SIZE="-0.6634280275543899" NO="2" P_CHI2="1.0" P_Z="9.288950431375148E-5" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0" Z="3.908451722256757">
<NAME>Number of patients with arthritis episodes</NAME>
<DICH_DATA CI_END="0.46693882508580975" CI_START="0.10089832547827349" EFFECT_SIZE="0.21705608849316035" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="29" LOG_CI_END="-0.33074001379781853" LOG_CI_START="-0.9961160413109613" LOG_EFFECT_SIZE="-0.6634280275543899" ORDER="138448" O_E="-10.0" SE="0.3908451722256757" STUDY_ID="STD-Calguneri-1996a" TOTAL_1="60" TOTAL_2="60" VAR="6.546218487394958" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.38529670275394123" CI_START="-0.8147032972460589" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2008-11-08 18:03:37 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="4.320463057692227E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="60" UNITS="" WEIGHT="100.00000000000001" Z="5.477225575051662">
<NAME>Mean of arthritis episodes per patient</NAME>
<GROUP_LABEL_1>Col+Ben-Pen</GROUP_LABEL_1>
<GROUP_LABEL_2>Colchcine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Col+Ben</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours colchicine</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.38529670275394123" CI_START="-0.8147032972460589" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.8" ORDER="138449" SD_1="0.6" SD_2="0.6" SE="0.10954451150103323" STUDY_ID="STD-Calguneri-1996a" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.4493817646021967" CI_START="-2.4493817646021965" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" MODIFIED="2008-11-08 18:03:37 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.615165191151791" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="49" UNITS="" WEIGHT="100.0" Z="0.5027142502638566">
<NAME>Duration of episode</NAME>
<GROUP_LABEL_1>Col+Ben-Pen</GROUP_LABEL_1>
<GROUP_LABEL_2>Colchcine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Col+Ben</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours colchicine</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.4493817646021967" CI_START="-2.4493817646021965" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="9.4" ORDER="138450" SD_1="3.1" SD_2="3.5" SE="0.9946008089835687" STUDY_ID="STD-Calguneri-1996a" TOTAL_1="13" TOTAL_2="49" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.3822095825190397" CI_START="0.15694950419337345" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7285850101768769" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.5292005156542031" LOG_CI_START="-0.8042400519067365" LOG_EFFECT_SIZE="-0.13751976812626673" METHOD="PETO" MODIFIED="2008-11-08 18:03:37 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.6860155261683704" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="49" WEIGHT="100.0" Z="0.40426817549551436">
<NAME>Severe arthritis attacks</NAME>
<GROUP_LABEL_1>Col+Ben-Pen</GROUP_LABEL_1>
<GROUP_LABEL_2>Colchcine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Col+Ben</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours colchicine</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3822095825190397" CI_START="0.15694950419337345" EFFECT_SIZE="0.7285850101768769" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="0.5292005156542031" LOG_CI_START="-0.8042400519067365" LOG_EFFECT_SIZE="-0.13751976812626673" ORDER="138451" O_E="-0.5161290322580645" SE="0.7832695900225591" STUDY_ID="STD-Calguneri-1996a" TOTAL_1="13" TOTAL_2="49" VAR="1.6299619590249226" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.714398245772431" CI_START="0.101269456177989" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9394159735004486" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.940237403200071" LOG_CI_START="-0.9945215221972814" LOG_EFFECT_SIZE="-0.027142059498605244" METHOD="PETO" MODIFIED="2008-11-08 18:03:37 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.9561453909156327" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="49" WEIGHT="99.99999999999999" Z="0.05499130499949405">
<NAME>Polyarticular joint involvement</NAME>
<GROUP_LABEL_1>Col+Ben-Pen</GROUP_LABEL_1>
<GROUP_LABEL_2>Colchcine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Col+Ben</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours colchicine</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.714398245772431" CI_START="0.101269456177989" EFFECT_SIZE="0.9394159735004486" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.940237403200071" LOG_CI_START="-0.9945215221972814" LOG_EFFECT_SIZE="-0.027142059498605244" ORDER="138452" O_E="-0.048387096774193505" SE="1.1364869699895448" STUDY_ID="STD-Calguneri-1996a" TOTAL_1="13" TOTAL_2="49" VAR="0.7742319305368384" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7052256242868726" CI_START="-1.3052256242868723" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.07" MODIFIED="2008-11-08 18:03:37 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.558593068789797" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="49" UNITS="" WEIGHT="100.0" Z="0.5849325575829282">
<NAME>Prednisone dosage/day</NAME>
<GROUP_LABEL_1>Col+Ben-Pen</GROUP_LABEL_1>
<GROUP_LABEL_2>Colchcine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Col+Ben</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours colchicine</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7052256242868726" CI_START="-1.3052256242868723" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="6.1" ORDER="138453" SD_1="1.6" SD_2="1.8" SE="0.5128796407566485" STUDY_ID="STD-Calguneri-1996a" TOTAL_1="13" TOTAL_2="49" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.0195808804236575" CI_START="-2.4195808804236596" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7000000000000011" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.08" MODIFIED="2008-11-08 18:03:37 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.42495512434469207" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="49" UNITS="" WEIGHT="100.0" Z="0.7978541776063609">
<NAME>Prednisone duration/days</NAME>
<GROUP_LABEL_1>Col+Ben-Pen</GROUP_LABEL_1>
<GROUP_LABEL_2>Colchcine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Col+Ben</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours colchicine</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0195808804236575" CI_START="-2.4195808804236596" EFFECT_SIZE="-0.7000000000000011" ESTIMABLE="YES" MEAN_1="12.1" MEAN_2="12.8" ORDER="138454" SD_1="2.7" SD_2="3.2" SE="0.8773533054624947" STUDY_ID="STD-Calguneri-1996a" TOTAL_1="13" TOTAL_2="49" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.991796710413169" CI_START="4.608203289586829" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.799999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.09" MODIFIED="2008-11-08 18:03:37 -0500" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="1.4510289949777555E-21" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="60" UNITS="" WEIGHT="100.0" Z="9.538364228569945">
<NAME>Duration of arthritis episode-free period</NAME>
<GROUP_LABEL_1>Col+Ben-Pen</GROUP_LABEL_1>
<GROUP_LABEL_2>Colchcine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Col+Ben</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours colchicine</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.991796710413169" CI_START="4.608203289586829" EFFECT_SIZE="5.799999999999999" ESTIMABLE="YES" MEAN_1="13.2" MEAN_2="7.4" ORDER="138455" SD_1="2.85" SD_2="3.75" SE="0.6080707195713341" STUDY_ID="STD-Calguneri-1996a" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.734585136531178" CI_START="0.3770276011402538" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1866093187230569" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-004.10" LOG_CI_END="0.5722423644051506" LOG_CI_START="-0.4236268551413491" LOG_EFFECT_SIZE="0.07430775463190076" METHOD="PETO" MODIFIED="2008-11-08 18:03:37 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.7699125748376188" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0" Z="0.29248925459687736">
<NAME>Colchicine gastro-intestinal side effects.</NAME>
<GROUP_LABEL_1>Col+Ben-Pen</GROUP_LABEL_1>
<GROUP_LABEL_2>Colchcine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Col+Ben</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours colchicine</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.734585136531177" CI_START="0.37702760114025385" EFFECT_SIZE="1.1866093187230569" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5722423644051505" LOG_CI_START="-0.42362685514134907" LOG_EFFECT_SIZE="0.07430775463190076" ORDER="138456" O_E="0.5" SE="0.5849785091937547" STUDY_ID="STD-Calguneri-1996a" TOTAL_1="60" TOTAL_2="60" VAR="2.922268907563025" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Topical alpha interpheron vs placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="10.196001086655158" CI_START="-4.396001086655154" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.900000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.4359546356702806" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="31" UNITS="" WEIGHT="100.0" Z="0.7790425861589252">
<NAME>New oral ulcers (per group)</NAME>
<GROUP_LABEL_1>Alpha interpheron</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours a-interpher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.196001086655158" CI_START="-4.396001086655154" EFFECT_SIZE="2.900000000000002" ESTIMABLE="YES" MEAN_1="23.1" MEAN_2="20.2" ORDER="138457" SD_1="15.8" SD_2="13.1" SE="3.7225179361483587" STUDY_ID="STD-Hamuryudan-1991" TOTAL_1="30" TOTAL_2="31" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.0179801155905883" CI_START="0.0820198844094111" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0499999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.03350012357375244" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="31" UNITS="" WEIGHT="100.0" Z="2.1260376640189995">
<NAME>Total oral ulcers (per patient)</NAME>
<GROUP_LABEL_1>Alpha interpheron</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours a-interpher</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.0179801155905883" CI_START="0.0820198844094111" EFFECT_SIZE="1.0499999999999998" ESTIMABLE="YES" MEAN_1="3.28" MEAN_2="2.23" ORDER="138458" SD_1="2.2" SD_2="1.6" SE="0.49387648100980036" STUDY_ID="STD-Hamuryudan-1991" TOTAL_1="30" TOTAL_2="31" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2008-11-08 18:03:55 -0500" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Azaproprazone vs placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.532673993407517" CI_START="0.5767233958817121" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.6168175957425452" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.6563544841247285" LOG_CI_START="-0.23903243024987963" LOG_EFFECT_SIZE="0.20866102693742442" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.36097949769673465" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0" Z="0.9135002783911395">
<NAME>Persistence of arthritis</NAME>
<GROUP_LABEL_1>Azaproprazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azaprop</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.532673993407516" CI_START="0.5767233958817122" EFFECT_SIZE="1.6168175957425452" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.6563544841247284" LOG_CI_START="-0.23903243024987955" LOG_EFFECT_SIZE="0.20866102693742442" ORDER="138459" O_E="1.7368421052631575" SE="0.5259547057403531" STUDY_ID="STD-Moral-1995" TOTAL_1="28" TOTAL_2="29" VAR="3.6149584487534625" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.978179761969872" CI_START="0.19098199459375256" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6146517034923118" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.2962657544422911" LOG_CI_START="-0.7190075752505795" LOG_EFFECT_SIZE="-0.2113709104041442" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.41444623039562456" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0" Z="0.8160942667466476">
<NAME>New arthritis</NAME>
<GROUP_LABEL_1>Azaproprazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azaprop</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.978179761969872" CI_START="0.19098199459375256" EFFECT_SIZE="0.6146517034923118" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.2962657544422911" LOG_CI_START="-0.7190075752505795" LOG_EFFECT_SIZE="-0.2113709104041442" ORDER="138460" O_E="-1.3684210526315788" SE="0.5963765795456273" STUDY_ID="STD-Moral-1995" TOTAL_1="28" TOTAL_2="29" VAR="2.811634349030471" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.484652441984778" CI_START="-4.08465244198478" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.9271051163772344" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="0.09148765324975267">
<NAME>Duration of arthritis (mean±sd days)</NAME>
<GROUP_LABEL_1>Azaproprazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azaprop</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.484652441984778" CI_START="-4.08465244198478" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="19.9" MEAN_2="19.7" ORDER="138461" SD_1="8.3" SD_2="8.2" SE="2.1860873341457143" STUDY_ID="STD-Moral-1995" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5209697434356401" CI_START="-0.5209697434356401" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Joint swelling day 7</NAME>
<GROUP_LABEL_1>Azaproprazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azaprop</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5209697434356401" CI_START="-0.5209697434356401" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.1" ORDER="138462" SD_1="0.9" SD_2="1.1" SE="0.2658057737514479" STUDY_ID="STD-Moral-1995" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6192870642980121" CI_START="-0.4192870642980121" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.7058513840874692" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="0.37743362376830863">
<NAME>Joint swelling day 21</NAME>
<GROUP_LABEL_1>Azaproprazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azaprop</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6192870642980121" CI_START="-0.4192870642980121" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="0.8" ORDER="138463" SD_1="1.0" SD_2="1.0" SE="0.26494724821174376" STUDY_ID="STD-Moral-1995" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.6956954349064088E-32" CI_END="0.2177576428349959" CI_START="-0.6177576428349961" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2000000000000001" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-006.06" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="0.34807698845452784" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="0.9383258538320473">
<NAME>Tender joint score 7</NAME>
<GROUP_LABEL_1>Azaproprazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azaprop</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.21775764283499593" CI_START="-0.617757642834996" EFFECT_SIZE="-0.20000000000000007" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="1.1" ORDER="138464" SD_1="0.7" SD_2="0.9" SE="0.21314557110753818" STUDY_ID="STD-Moral-1995" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5426114979687799" CI_START="-0.34261149796877977" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.6578972856432554" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="0.44281813588997737">
<NAME>Tender joint score 21</NAME>
<GROUP_LABEL_1>Azaproprazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azaprop</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5426114979687799" CI_START="-0.34261149796877977" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.7" ORDER="138465" SD_1="0.9" SD_2="0.8" SE="0.2258263424532506" STUDY_ID="STD-Moral-1995" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.21208170830555884" CI_START="-3.1879182916944417" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.025134508843691422" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="2.2393291300449576">
<NAME>Visual analogue scale for pain day 7</NAME>
<GROUP_LABEL_1>Azaproprazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azaprop</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.21208170830555884" CI_START="-3.1879182916944417" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="4.2" ORDER="138466" SD_1="2.5" SD_2="3.2" SE="0.7591559352268464" STUDY_ID="STD-Moral-1995" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.1389722287830515" CI_START="-1.1389722287830515" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.09" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.549890175399262" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="0.5979247085825674">
<NAME>Visual analogue score for pain day 21</NAME>
<GROUP_LABEL_1>Azaproprazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azaprop</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.1389722287830515" CI_START="-1.1389722287830515" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="1.9" ORDER="138467" SD_1="3.3" SD_2="3.0" SE="0.8362256866509055" STUDY_ID="STD-Moral-1995" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.605021972300444" CI_START="-0.605021972300444" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.10" MODIFIED="2008-11-08 18:03:55 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.22203128189507293" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="1.221144643727761">
<NAME>Mean C reactive protein (mg/dl) day 21</NAME>
<GROUP_LABEL_1>Azaproprazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azaprop</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.605021972300444" CI_START="-0.605021972300444" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="2.0" ORDER="138468" SD_1="3.5" SD_2="2.6" SE="0.8189038089274356" STUDY_ID="STD-Moral-1995" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="15.476418652676632" CI_START="-11.276418652676629" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.1000000000000014" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.11" MODIFIED="2008-11-08 18:03:55 -0500" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.7583106003669613" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="29" UNITS="" WEIGHT="100.00000000000001" Z="0.30770002602382046">
<NAME>Mean erythrocyte sedimentation rate day 21</NAME>
<GROUP_LABEL_1>Azaproprazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azaprop</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="15.476418652676632" CI_START="-11.276418652676629" EFFECT_SIZE="2.1000000000000014" ESTIMABLE="YES" MEAN_1="45.1" MEAN_2="43.0" ORDER="138469" SD_1="29.5" SD_2="21.2" SE="6.824828802053565" STUDY_ID="STD-Moral-1995" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Cyclosporine vs cyclophosphamide</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.1212918407078325" CI_START="-2.521291840707833" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6368577114130978" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="99.99999999999999" Z="0.47209678126264193">
<NAME>Visual acuity</NAME>
<GROUP_LABEL_1>Cyclosporine</GROUP_LABEL_1>
<GROUP_LABEL_2>Cyclophosphamide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclospor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cyclophosph</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.1212918407078325" CI_START="-2.521291840707833" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="4.75" MEAN_2="3.95" ORDER="138470" SD_1="4.84" SD_2="2.3" SE="1.6945677915031903" STUDY_ID="STD-Oryazgan-1992" TOTAL_1="10" TOTAL_2="10" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.07043180248415082" CI_START="-0.35043180248415084" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.14" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.1922467273333031" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="11" UNITS="" WEIGHT="100.0" Z="1.3039614478247619">
<NAME>Number of ocular attacks/patient/month up to 6 months.</NAME>
<GROUP_LABEL_1>Cyclosporine</GROUP_LABEL_1>
<GROUP_LABEL_2>Cyclophosphamide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclospor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cyclophosph</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.07043180248415082" CI_START="-0.35043180248415084" EFFECT_SIZE="-0.14" ESTIMABLE="YES" MEAN_1="0.48" MEAN_2="0.62" ORDER="138471" SD_1="0.28" SD_2="0.22" SE="0.10736513739232456" STUDY_ID="STD-Oryazgan-1992" TOTAL_1="11" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.34143038271457027" CI_START="-0.5614303827145702" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.10999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.6329461485824628" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.47758424455830806">
<NAME>Number of ocular attacks/patient/month from 6 months to unmasking.</NAME>
<GROUP_LABEL_1>Cyclosporine</GROUP_LABEL_1>
<GROUP_LABEL_2>Cyclophosphamide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclospor</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cyclophosph</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.34143038271457027" CI_START="-0.5614303827145702" EFFECT_SIZE="-0.10999999999999999" ESTIMABLE="YES" MEAN_1="0.49" MEAN_2="0.6" ORDER="138472" SD_1="0.52" SD_2="0.51" SE="0.23032585612562043" STUDY_ID="STD-Oryazgan-1992" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Autologous salive vs placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.872164777389823" CI_START="0.38003096790202656" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.3607253566130149" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.687721967781841" LOG_CI_START="-0.4201810122227196" LOG_EFFECT_SIZE="0.13377047777956072" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6359990627339938" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="14" WEIGHT="100.0" Z="0.4733001415730019">
<NAME>Oral aphtas improvement</NAME>
<GROUP_LABEL_1>Autologous saliva</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours autolog sal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.872164777389823" CI_START="0.38003096790202656" EFFECT_SIZE="1.3607253566130149" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.687721967781841" LOG_CI_START="-0.4201810122227196" LOG_EFFECT_SIZE="0.13377047777956072" ORDER="138473" O_E="0.7272727272727266" SE="0.6507876946628781" STUDY_ID="STD-Benamour-1991" TOTAL_1="30" TOTAL_2="14" VAR="2.361137805112435" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.609577595742405" CI_START="0.2142392954048999" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1899711118493026" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.8201737055219542" LOG_CI_START="-0.6691008686473535" LOG_EFFECT_SIZE="0.0755364184373004" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8424036828011454" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="14" WEIGHT="100.0" Z="0.19881983111252016">
<NAME>Genital aphtas improvement</NAME>
<GROUP_LABEL_1>Autologous saliva</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours autolog sal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.609577595742404" CI_START="0.21423929540489994" EFFECT_SIZE="1.1899711118493026" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.8201737055219541" LOG_CI_START="-0.6691008686473534" LOG_EFFECT_SIZE="0.0755364184373004" ORDER="138474" O_E="0.22727272727272751" SE="0.8748072568950879" STUDY_ID="STD-Benamour-1991" TOTAL_1="30" TOTAL_2="14" VAR="1.3066980588122235" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Arthritis improvement</NAME>
<GROUP_LABEL_1>Autologous saliva</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours autolog sal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="138475" O_E="0.0" SE="0.0" STUDY_ID="STD-Benamour-1991" TOTAL_1="30" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Cyclosporine vs conventional therapy.</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8376421925671652" CI_START="0.04718850362878439" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.19881418873807422" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-0.07694145509044412" LOG_CI_START="-1.3261637941354465" LOG_EFFECT_SIZE="-0.7015526246129452" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.02770784935827144" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="2.2013981571160284">
<NAME>Drop-outs due to severe eye involvement</NAME>
<GROUP_LABEL_1>Cyclosporin</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclosporin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8376421925671652" CI_START="0.04718850362878439" EFFECT_SIZE="0.19881418873807422" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.07694145509044412" LOG_CI_START="-1.3261637941354465" LOG_EFFECT_SIZE="-0.7015526246129452" ORDER="138476" O_E="-3.0" SE="0.7337993857053429" STUDY_ID="STD-Benezra-1988" TOTAL_1="18" TOTAL_2="18" VAR="1.857142857142857" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.25671483865690636" CI_START="-0.11671483865690638" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.07" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.4624632196531131" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="0.7347968694116911">
<NAME>Visual acuity at 1st month</NAME>
<GROUP_LABEL_1>Cyclosporin</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclosporin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.25671483865690636" CI_START="-0.11671483865690638" EFFECT_SIZE="0.07" ESTIMABLE="YES" MEAN_1="0.45" MEAN_2="0.38" ORDER="138477" SD_1="0.38" SD_2="0.32" SE="0.09526442329026921" STUDY_ID="STD-Benezra-1988" TOTAL_1="29" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.402896433519043" CI_START="-0.16289643351904298" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.12" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.40575652397155637" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="99.99999999999999" Z="0.831384387633061">
<NAME>Visual acuity at 24 month</NAME>
<GROUP_LABEL_1>Cyclosporin</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclosporin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.402896433519043" CI_START="-0.16289643351904298" EFFECT_SIZE="0.12" ESTIMABLE="YES" MEAN_1="0.45" MEAN_2="0.33" ORDER="138478" SD_1="0.4" SD_2="0.3" SE="0.14433756729740646" STUDY_ID="STD-Benezra-1988" TOTAL_1="12" TOTAL_2="12" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1283.9691699882123" CI_START="0.3142044240022041" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="20.08553692318765" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="3.108554595800791" LOG_CI_START="-0.502787704381281" LOG_EFFECT_SIZE="1.3028834457097551" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.1572992070526332" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="1" WEIGHT="100.0" Z="1.4142135623730947">
<NAME>Mouth ulcers: 0-24 months</NAME>
<GROUP_LABEL_1>Cyclosporin</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclosporin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_DATA CI_END="1283.9691699882123" CI_START="0.3142044240022041" EFFECT_SIZE="20.08553692318765" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="3.108554595800791" LOG_CI_START="-0.502787704381281" LOG_EFFECT_SIZE="1.3028834457097551" ORDER="138479" O_E="0.6666666666666665" SE="2.1213203435596424" STUDY_ID="STD-Benezra-1988" TOTAL_1="5" TOTAL_2="1" VAR="0.22222222222222224" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Genital ulcers:0-24 months</NAME>
<GROUP_LABEL_1>Cyclosporin</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclosporin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="138480" O_E="0.0" SE="0.0" STUDY_ID="STD-Benezra-1988" TOTAL_1="5" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>Colchicine vs placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="16.15145188991632" CI_START="0.5610595029164874" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.0103032353462353" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="1.208211568118358" LOG_CI_START="-0.25099107739282345" LOG_EFFECT_SIZE="0.47861024536276736" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.19854279368173477" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0" Z="1.2857142857142858">
<NAME>Aphtas not improved</NAME>
<GROUP_LABEL_1>Colchicine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Colchicine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.15145188991632" CI_START="0.5610595029164874" EFFECT_SIZE="3.0103032353462353" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.208211568118358" LOG_CI_START="-0.25099107739282345" LOG_EFFECT_SIZE="0.47861024536276736" ORDER="138481" O_E="1.5" SE="0.8571428571428572" STUDY_ID="STD-Aktulga-1980" TOTAL_1="14" TOTAL_2="14" VAR="1.361111111111111" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.7767193521108906" CI_START="0.05908041857113833" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4723665527410146" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="0.5771147136180791" LOG_CI_START="-1.2285564364729569" LOG_EFFECT_SIZE="-0.325720861427439" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.4795001272643742" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="8" WEIGHT="100.0" Z="0.7071067811865478">
<NAME>Eye not improved</NAME>
<GROUP_LABEL_1>Colchicine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Colchicine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.7767193521108906" CI_START="0.05908041857113833" EFFECT_SIZE="0.4723665527410146" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.5771147136180791" LOG_CI_START="-1.2285564364729569" LOG_EFFECT_SIZE="-0.325720861427439" ORDER="138482" O_E="-0.666666666666667" SE="1.0606601717798212" STUDY_ID="STD-Aktulga-1980" TOTAL_1="7" TOTAL_2="8" VAR="0.8888888888888891" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.434697736631353" CI_START="0.34255880166283487" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.2994111334618923" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="1.1884981289526497" LOG_CI_START="-0.4652648692933564" LOG_EFFECT_SIZE="0.3616166298296466" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.39136594706505556" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="7" WEIGHT="100.0" Z="0.8571428571428575">
<NAME>Genital ulcers not improved</NAME>
<GROUP_LABEL_1>Colchicine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Colchicine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.434697736631346" CI_START="0.3425588016628349" EFFECT_SIZE="2.2994111334618923" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1884981289526495" LOG_CI_START="-0.4652648692933563" LOG_EFFECT_SIZE="0.3616166298296466" ORDER="138483" O_E="0.882352941176471" SE="0.9714285714285714" STUDY_ID="STD-Aktulga-1980" TOTAL_1="10" TOTAL_2="7" VAR="1.0596885813148789" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.610794904918433" CI_START="0.03957460628948981" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5488116360940263" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-010.04" LOG_CI_END="0.8814300187667345" LOG_CI_START="-1.4025833970506367" LOG_EFFECT_SIZE="-0.2605766891419512" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6547208473654283" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="4" WEIGHT="100.0" Z="0.4472135954999581">
<NAME>Erythema nodosum not improved</NAME>
<GROUP_LABEL_1>Colchicine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Colchicine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.610794904918433" CI_START="0.03957460628948981" EFFECT_SIZE="0.5488116360940263" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.8814300187667345" LOG_CI_START="-1.4025833970506367" LOG_EFFECT_SIZE="-0.2605766891419512" ORDER="138484" O_E="-0.3333333333333335" SE="1.3416407864998738" STUDY_ID="STD-Aktulga-1980" TOTAL_1="5" TOTAL_2="4" VAR="0.5555555555555556" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.965692797786113" CI_START="0.31124106235831533" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.4724162544758244" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-010.05" LOG_CI_END="0.842964317212621" LOG_CI_START="-0.506903110977962" LOG_EFFECT_SIZE="0.16803060311732945" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.6255852332612349" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0" Z="0.48795003647426627">
<NAME>Pyoderma not improved</NAME>
<GROUP_LABEL_1>Colchicine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Colchicine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.965692797786115" CI_START="0.3112410623583153" EFFECT_SIZE="1.4724162544758244" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.8429643172126211" LOG_CI_START="-0.506903110977962" LOG_EFFECT_SIZE="0.16803060311732945" ORDER="138485" O_E="0.615384615384615" SE="0.7929188092706833" STUDY_ID="STD-Aktulga-1980" TOTAL_1="12" TOTAL_2="14" VAR="1.5905325443786982" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.113871663627698" CI_START="0.04633040761802166" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4867522559599717" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-010.06" LOG_CI_END="0.7087498248874857" LOG_CI_START="-1.3341338788281683" LOG_EFFECT_SIZE="-0.31269202697034126" METHOD="PETO" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.5485062386641546" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="0.6">
<NAME>Arthritis not improved</NAME>
<GROUP_LABEL_1>Colchicine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Colchicine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.113871663627698" CI_START="0.04633040761802166" EFFECT_SIZE="0.4867522559599717" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.7087498248874857" LOG_CI_START="-1.3341338788281683" LOG_EFFECT_SIZE="-0.31269202697034126" ORDER="138486" O_E="-0.5" SE="1.2" STUDY_ID="STD-Aktulga-1980" TOTAL_1="5" TOTAL_2="5" VAR="0.6944444444444444" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="11.778924704519607" CI_START="0.06119481318172891" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8490047684051771" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-010.07" LOG_CI_END="1.0711056456116232" LOG_CI_START="-1.213285386710902" LOG_EFFECT_SIZE="-0.07108987054963938" METHOD="PETO" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.9029089106865814" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="4" WEIGHT="100.0" Z="0.12198750911856655">
<NAME>Arthralgia not improved</NAME>
<GROUP_LABEL_1>Colchicine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Colchicine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.778924704519607" CI_START="0.06119481318172891" EFFECT_SIZE="0.8490047684051771" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="1.0711056456116232" LOG_CI_START="-1.213285386710902" LOG_EFFECT_SIZE="-0.07108987054963938" ORDER="138487" O_E="-0.09090909090909083" SE="1.341862600304233" STUDY_ID="STD-Aktulga-1980" TOTAL_1="7" TOTAL_2="4" VAR="0.5553719008264463" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="17.699969776257152" CI_START="0.06356337659624328" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0606930963433097" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-010.08" LOG_CI_END="1.2479725247789848" LOG_CI_START="-1.1967930403796117" LOG_EFFECT_SIZE="0.025589742199686568" METHOD="PETO" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.9672715832398173" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="18" WEIGHT="100.0" Z="0.041030496993110926">
<NAME>Bilateral eye involvement</NAME>
<GROUP_LABEL_1>Colchicine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Colchicine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="17.699969776257145" CI_START="0.06356337659624331" EFFECT_SIZE="1.0606930963433097" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2479725247789846" LOG_CI_START="-1.1967930403796114" LOG_EFFECT_SIZE="0.025589742199686568" ORDER="138488" O_E="0.02857142857142858" SE="1.4360673947588818" STUDY_ID="STD-Aktulga-1980" TOTAL_1="17" TOTAL_2="18" VAR="0.48489795918367345" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2008-11-08 18:04:03 -0500" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Cyclosporine vs Colchicine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.22549095180908213" CI_START="0.041403826686950376" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.09662395297325976" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="-0.6468708802083096" LOG_CI_START="-1.382959518004115" LOG_EFFECT_SIZE="-1.0149151991062124" METHOD="PETO" MODIFIED="2008-11-08 18:04:03 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="6.488930051264408E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="46" WEIGHT="100.0" Z="5.404776369234726">
<NAME>Ocular attacks frequency:not improvemed</NAME>
<GROUP_LABEL_1>Cyclosporine</GROUP_LABEL_1>
<GROUP_LABEL_2>Colchicine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclosporine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours colchicine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.22549095180908219" CI_START="0.041403826686950355" EFFECT_SIZE="0.09662395297325976" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="29" LOG_CI_END="-0.6468708802083095" LOG_CI_START="-1.3829595180041152" LOG_EFFECT_SIZE="-1.0149151991062124" ORDER="138489" O_E="-12.5" SE="0.4323821095387781" STUDY_ID="STD-Masuda-1989" TOTAL_1="46" TOTAL_2="46" VAR="5.348901098901099" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.22549095180908213" CI_START="0.041403826686950376" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.09662395297325976" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="-0.6468708802083096" LOG_CI_START="-1.382959518004115" LOG_EFFECT_SIZE="-1.0149151991062124" METHOD="PETO" MODIFIED="2008-11-08 18:04:03 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="6.488930051264408E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="46" WEIGHT="100.0" Z="5.404776369234726">
<NAME>Ocular attacks severity:not improved</NAME>
<GROUP_LABEL_1>Cyclosporine</GROUP_LABEL_1>
<GROUP_LABEL_2>Colchicine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclosporine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours colchicine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.22549095180908219" CI_START="0.041403826686950355" EFFECT_SIZE="0.09662395297325976" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="29" LOG_CI_END="-0.6468708802083095" LOG_CI_START="-1.3829595180041152" LOG_EFFECT_SIZE="-1.0149151991062124" ORDER="138490" O_E="-12.5" SE="0.4323821095387781" STUDY_ID="STD-Masuda-1989" TOTAL_1="46" TOTAL_2="46" VAR="5.348901098901099" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7546134497424148" CI_START="0.12137163056947592" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.3026361922257385" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="-0.12227545848188379" LOG_CI_START="-0.9158828134826654" LOG_EFFECT_SIZE="-0.5190791359822746" METHOD="PETO" MODIFIED="2008-11-08 18:04:03 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.010349474648066936" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="46" WEIGHT="100.0" Z="2.563928888109727">
<NAME>Dermal lesions not improved</NAME>
<GROUP_LABEL_1>Cyclosporine</GROUP_LABEL_1>
<GROUP_LABEL_2>Colchicine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclosporine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours colchicine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7546134497424146" CI_START="0.12137163056947592" EFFECT_SIZE="0.3026361922257385" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="39" LOG_CI_END="-0.12227545848188394" LOG_CI_START="-0.9158828134826654" LOG_EFFECT_SIZE="-0.5190791359822746" ORDER="138491" O_E="-5.5" SE="0.46616888874722306" STUDY_ID="STD-Masuda-1989" TOTAL_1="46" TOTAL_2="46" VAR="4.601648351648352" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.30972530342647475" CI_START="0.060727876581035074" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.13714576187584726" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-011.04" LOG_CI_END="-0.5090233129202789" LOG_CI_START="-1.2166119042102497" LOG_EFFECT_SIZE="-0.8628176085652642" METHOD="PETO" MODIFIED="2008-11-08 18:04:03 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="1.754068569858527E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="46" WEIGHT="100.0" Z="4.779871973153069">
<NAME>Aphtas not improved</NAME>
<GROUP_LABEL_1>Cyclosporine</GROUP_LABEL_1>
<GROUP_LABEL_2>Colchicine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclosporine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours colchicine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.30972530342647475" CI_START="0.060727876581035074" EFFECT_SIZE="0.13714576187584726" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="36" LOG_CI_END="-0.5090233129202789" LOG_CI_START="-1.2166119042102497" LOG_EFFECT_SIZE="-0.8628176085652642" ORDER="138492" O_E="-11.5" SE="0.41564104114374517" STUDY_ID="STD-Masuda-1989" TOTAL_1="46" TOTAL_2="46" VAR="5.788461538461539" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.4010510652004458" CI_START="0.029441269186382783" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.10866210180210892" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-011.05" LOG_CI_END="-0.3968003258266795" LOG_CI_START="-1.5310434718901944" LOG_EFFECT_SIZE="-0.9639218988584368" METHOD="PETO" MODIFIED="2008-11-08 18:04:03 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="8.644133004124781E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="46" WEIGHT="100.0" Z="3.3313001929591626">
<NAME>Clinical symptoms aggravated</NAME>
<GROUP_LABEL_1>Cyclosporine</GROUP_LABEL_1>
<GROUP_LABEL_2>Colchicine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclosporine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours colchicine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4010510652004457" CI_START="0.029441269186382797" EFFECT_SIZE="0.10866210180210892" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" LOG_CI_END="-0.3968003258266796" LOG_CI_START="-1.5310434718901942" LOG_EFFECT_SIZE="-0.9639218988584368" ORDER="138493" O_E="-5.0" SE="0.6662600385918325" STUDY_ID="STD-Masuda-1989" TOTAL_1="46" TOTAL_2="46" VAR="2.252747252747253" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" NO="12">
<NAME>Acyclovir vs placebo.</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="18.97904369254308" CI_START="-12.379043692543076" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.3000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6799600995672512" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="100.0" Z="0.4125175792486816">
<NAME>Frequency new oral ulcers.</NAME>
<GROUP_LABEL_1>Acyclovir</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acyclovir</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="18.97904369254308" CI_START="-12.379043692543076" EFFECT_SIZE="3.3000000000000007" ESTIMABLE="YES" MEAN_1="25.1" MEAN_2="21.8" ORDER="138494" SD_1="29.8" SD_2="22.8" SE="7.999659083645094" STUDY_ID="STD-Davies-1988" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.28264044243128" CI_START="-9.28264044243128" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Frequency new genital ulcers.</NAME>
<GROUP_LABEL_1>Acyclovir</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acyclovir</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.28264044243128" CI_START="-9.28264044243128" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="6.4" MEAN_2="6.4" ORDER="138495" SD_1="16.2" SD_2="15.2" SE="4.736128069521462" STUDY_ID="STD-Davies-1988" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="10.676463094387529" CI_START="-1.4764630943875252" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.600000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.13788040069316182" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="100.0" Z="1.4837306157938572">
<NAME>Erythrocyte sedimentation rate mm/h.</NAME>
<GROUP_LABEL_1>Acyclovir</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acyclovir</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.676463094387529" CI_START="-1.4764630943875252" EFFECT_SIZE="4.600000000000001" ESTIMABLE="YES" MEAN_1="16.1" MEAN_2="11.5" ORDER="138496" SD_1="11.5" SD_2="8.9" SE="3.1002932412625395" STUDY_ID="STD-Davies-1988" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5802361179245524" CI_START="-0.7802361179245517" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7732472680932362" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="100.0" Z="0.28812994971805295">
<NAME>Hemoglobine g/dl.</NAME>
<GROUP_LABEL_1>Acyclovir</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acyclovir</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5802361179245524" CI_START="-0.7802361179245517" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="13.5" MEAN_2="13.6" ORDER="138497" SD_1="1.1" SD_2="1.2" SE="0.34706562125129226" STUDY_ID="STD-Davies-1988" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9046173397145272" CI_START="-1.1046173397145265" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.8453181260579923" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="100.0" Z="0.1950955759032581">
<NAME>White cell count, 10*9/l.</NAME>
<GROUP_LABEL_1>Acyclovir</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acyclovir</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9046173397145272" CI_START="-1.1046173397145265" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="7.1" ORDER="138498" SD_1="1.7" SD_2="1.7" SE="0.5125692857821982" STUDY_ID="STD-Davies-1988" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.525384876898422" CI_START="-1.7253848768984212" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.9040200608182174" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="100.0" Z="0.12058460813786293">
<NAME>Inmunoglobulin G, g/l.</NAME>
<GROUP_LABEL_1>Acyclovir</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acyclovir</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.525384876898422" CI_START="-1.7253848768984212" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="9.5" ORDER="138499" SD_1="2.7" SD_2="2.8" SE="0.8292932368753967" STUDY_ID="STD-Davies-1988" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-11-08 18:00:03 -0500" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-11-08 18:00:03 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-11-08 17:59:57 -0500" MODIFIED_BY="[Empty name]">Full search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-08 18:00:03 -0500" MODIFIED_BY="[Empty name]">
<P>001 behcet's syndrome/ 3007<BR/>002 triple symptom complex.tw. 6<BR/>003 behcet$.tw. 2831<BR/>004 or/1-3 3281<BR/>005 clinical trial.pt. 205256<BR/>006 randomized controlled trial.pt. 89327<BR/>007 random allocation/ 36248<BR/>008 exp clinical trials/ 97627<BR/>009 exp longitudinal studies/ 275490<BR/>010 double-blind method/ 49155<BR/>011 single-blind method/ 3268<BR/>012 placebos/ 17977<BR/>013 random$.tw. 143168<BR/>014 placebo$.tw. 49182<BR/>015 (control or controls or controlled).tw. 717939<BR/>016 (double adj blind$).tw. 44078<BR/>017 or/5-16 1167549<BR/>018 4 and 17 480</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>